{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "33bad7bd-ba8a-4fdb-9d9e-5951efa9ab2d",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "# Projeto - Extração de Dados I\n",
    "\n",
    "## Sistema de Monitoramento de Avanços no Campo da Genômica\n",
    "\n",
    "### Contexto:\n",
    "\n",
    "O grupo trabalha no time de engenharia de dados na HealthGen, uma empresa especializada em genômica e pesquisa de medicina personalizada. A genômica é o estudo do conjunto completo de genes de um organismo, desempenha um papel fundamental na medicina personalizada e na pesquisa biomédica. Permite a análise do DNA para identificar variantes genéticas e mutações associadas a doenças e facilita a personalização de tratamentos com base nas características genéticas individuais dos pacientes.\n",
    "\n",
    "A empresa precisa se manter atualizada sobre os avanços mais recentes na genômica, identificar oportunidades para pesquisa e desenvolvimento de tratamentos personalizados e acompanhar as tendências em genômica que podem influenciar estratégias de pesquisa e desenvolvimento. Pensando nisso, o time de dados apresentou uma proposta de desenvolvimento de um sistema que coleta, analisa e apresenta as últimas notícias relacionadas à genômica e à medicina personalizada, e também estuda o avanço do campo nos últimos anos.\n",
    "\n",
    "O time de engenharia de dados tem como objetivo desenvolver e garantir um pipeline de dados confiável e estável. As principais atividades são:\n",
    "\n",
    "1. **Consumo de dados com a News API**:\n",
    "    - Implementar um mecanismo para consumir dados de notícias de fontes confiáveis e especializadas em genômica e medicina personalizada, a partir da News API:\n",
    "      [https://newsapi.org/](https://newsapi.org/)\n",
    "\n",
    "2. **Definir Critérios de Relevância**:\n",
    "    - Desenvolver critérios precisos de relevância para filtrar as notícias. Por exemplo, o time pode se concentrar em notícias que mencionem avanços em sequenciamento de DNA, terapias genéticas personalizadas ou descobertas relacionadas a doenças genéticas específicas.\n",
    "\n",
    "3. **Cargas em Batches**:\n",
    "    - Armazenar as notícias relevantes em um formato estruturado e facilmente acessível para consultas e análises posteriores. Essa carga deve acontecer 1 vez por hora. Se as notícias extraídas já tiverem sido armazenadas na carga anterior, o processo deve ignorar e não armazenar as notícias novamente, os dados carregados não podem ficar duplicados.\n",
    "\n",
    "4. **Dados transformados para consulta do público final**:\n",
    "    - A partir dos dados carregados, aplicar as seguintes transformações e armazenar o resultado final para a consulta do público final:\n",
    "        - Quantidade de notícias por ano, mês e dia de publicação;\n",
    "        - Quantidade de notícias por fonte e autor;\n",
    "        - Quantidade de aparições de 3 palavras-chave por ano, mês e dia de publicação (as 3 palavras-chave serão as mesmas usadas para fazer os filtros de relevância do item 2 (2. Definir Critérios de Relevância)).\n",
    "    - Atualizar os dados transformados 1 vez por dia."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "9f226638-8854-4f06-a3c2-34730c2c399b",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Uol.com.br\"\n    },\n    \"author\": \"Renata Turbiani\",\n    \"title\": null,\n    \"description\": \"Rejany Machado Pena e Jos\\u00e9 Carlos da Silva, moradores de Goi\\u00e2nia, se tornaram pais no dia 29 de novembro de 2000. Durante toda a gravidez, apesar de a futura mam\\u00e3e ter de lidar com um cisto de ov\\u00e1rio que s\\u00f3 crescia, o beb\\u00ea parecia bem.Mas tudo mudou ap\",\n    \"url\": \"https://www.uol.com.br/vivabem/noticias/redacao/2024/03/10/pais-levam-quase-20-anos-para-descobrir-doenca-ultrarrara-do-filho.htm\",\n    \"urlToImage\": \"https://conteudo.imguol.com.br/c/entretenimento/41/2024/03/06/joao-pedro-com-a-mae-1709724623447_v2_615x300.jpg\",\n    \"publishedAt\": \"2024-03-10T08:51:42Z\",\n    \"content\": \"S\\u00f3 que dessa vez foi diferente. Quando chegou o resultado, havia um diagn\\u00f3stico: defici\\u00eancia da descarboxilase dos amino\\u00e1cidos L-arom\\u00e1ticos (defici\\u00eancia de AADC). Finalmente, depois de 19 anos, soube\\u2026 [+1254 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Uol.com.br\"\n    },\n    \"author\": \"Ag\\u00eancia Fapesp\",\n    \"title\": \"Pesquisador da USP explica como ser\\u00e1 estudo cl\\u00ednico de terapia celular contra c\\u00e2ncer\",\n    \"description\": \"Os testes com c\\u00e9lulas CAR-T ser\\u00e3o exclusivos para pacientes com leucemia linfoide aguda de c\\u00e9lulas B e linfoma n\\u00e3o Hodgkin de c\\u00e9lulas B que n\\u00e3o responderam ou apresentaram o retorno da doen\\u00e7a ap\\u00f3s a primeira linha de tratamento convencional. Centro de Terapia\\u2026\",\n    \"url\": \"https://gizmodo.uol.com.br/pesquisador-da-usp-explica-como-sera-estudo-clinico-de-terapia-celular-contra-cancer/\",\n    \"urlToImage\": \"https://gizmodo.uol.com.br/wp-content/blogs.dir/8/files/2024/03/terapia-celular-fapesp.jpg\",\n    \"publishedAt\": \"2024-03-15T20:30:48Z\",\n    \"content\": \"Texto: Andr\\u00e9 Juli\\u00e3o | Ag\\u00eancia FAPESP*\\r\\nO dia 15 de mar\\u00e7o vai marcar o in\\u00edcio do que pode ser uma revolu\\u00e7\\u00e3o no tratamento de linfoma e leucemia na Am\\u00e9rica Latina. Nessa data, o Hospital das Cl\\u00ednicas d\\u2026 [+4363 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Olhardigital.com.br\"\n    },\n    \"author\": \"Leandro Costa Criscuolo\",\n    \"title\": \"SP d\\u00e1 in\\u00edcio a estudo cl\\u00ednico com c\\u00e9lulas CAR-T em tratamento contra leucemia e linfoma\",\n    \"description\": \"81 pacientes dever\\u00e3o receber o tratamento inovador em cinco hospitais do Estado, em S\\u00e3o Paulo (SP), Campinas (SP) e Ribeir\\u00e3o Preto (SP)\\nO post SP d\\u00e1 in\\u00edcio a estudo cl\\u00ednico com c\\u00e9lulas CAR-T em tratamento contra leucemia e linfoma apareceu primeiro em Olhar D\\u2026\",\n    \"url\": \"https://olhardigital.com.br/2024/03/25/medicina-e-saude/sp-da-inicio-a-estudo-clinico-com-celulas-car-t-em-tratamento-contra-leucemia-e-linfoma/\",\n    \"urlToImage\": \"https://olhardigital.com.br/wp-content/uploads/2024/03/leucemia-695x500.jpg\",\n    \"publishedAt\": \"2024-03-26T02:00:00Z\",\n    \"content\": \"J\\u00e1 hav\\u00edamos falado recentemente aqui como estava o estudo do tratamento revolucion\\u00e1rio com c\\u00e9lulas CAR-T. E, nesta segunda-feira, ocorreu o in\\u00edcio da operacionaliza\\u00e7\\u00e3o do N\\u00facleo de Terapia Avan\\u00e7ada (\\u2026 [+3178 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Olhardigital.com.br\"\n    },\n    \"author\": \"Alessandro Di Lorenzo\",\n    \"title\": \"CAR-T Cell: estudo revolucion\\u00e1rio contra o c\\u00e2ncer entrar\\u00e1 em nova etapa\",\n    \"description\": \"USP vai dar in\\u00edcio a nova fase de estudos do tratamento com c\\u00e9lulas CAR-T; no total, 81 pacientes ir\\u00e3o participar dos trabalhos\\nO post CAR-T Cell: estudo revolucion\\u00e1rio contra o c\\u00e2ncer entrar\\u00e1 em nova etapa apareceu primeiro em Olhar Digital.\",\n    \"url\": \"https://olhardigital.com.br/2024/03/14/medicina-e-saude/car-t-cell-estudo-revolucionario-contra-o-cancer-entrara-em-nova-etapa/\",\n    \"urlToImage\": \"https://olhardigital.com.br/wp-content/uploads/2024/03/celulas-CAR-T-695x500.png\",\n    \"publishedAt\": \"2024-03-14T08:40:00Z\",\n    \"content\": \"Um importante passo no tratamento de linfoma e leucemia na Am\\u00e9rica Latina. No dia 15 de mar\\u00e7o, o Hospital das Cl\\u00ednicas da Faculdade de Medicina de Ribeir\\u00e3o Preto da USP vai come\\u00e7ar o estudo cl\\u00ednico d\\u2026 [+3359 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Www.abc.es\"\n    },\n    \"author\": \"(abc)\",\n    \"title\": \"La terapia celular de nueva generaci\\u00f3n puede con un c\\u00e1ncer cerebral mortal\",\n    \"description\": \"Una nueva terapia celular, la terapia CAR-T de \\u00faltima generaci\\u00f3n, puede ser una nueva esperanza para las personas con una forma devastadora de c\\u00e1ncer cerebral, el glioblastoma. Un estudio realizado en el Hospital Mass General Cancer Center ha mostrado resulta\\u2026\",\n    \"url\": \"https://www.abc.es/salud/enfermedades/terapia-celular-nueva-generacion-puede-cancer-cerebral-20240313145908-nt.html\",\n    \"urlToImage\": \"https://s1.abcstatics.com/abc/www/multimedia/salud/2024/03/13/NewCells-U38051248666ocw-1024x512@diario_abc.png\",\n    \"publishedAt\": \"2024-03-13T21:00:11Z\",\n    \"content\": \"Una nueva terapia celular, la terapia CAR-T de \\u00faltima generaci\\u00f3n, puede ser una nueva esperanza para las personas con una forma devastadora de c\\u00e1ncer cerebral, el glioblastoma. Un estudio realizado e\\u2026 [+132 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Metropoles.com\"\n    },\n    \"author\": \"Beth\\u00e2nia Nunes\",\n    \"title\": \"Terapia CAR-T modificada reduz tumor cerebral grave de idoso em dias\",\n    \"description\": \"Atualmente, a terapia celular CAR-T \\u00e9 indicada apenas para certos tipos de c\\u00e2ncer de sangue. A pesquisa mostra uma nova possibilidade de uso\",\n    \"url\": \"https://www.metropoles.com/saude/car-t-diminui-tumor-cerebral\",\n    \"urlToImage\": \"https://uploads.metropoles.com/wp-content/uploads/2024/03/15123011/Idoso-tem-regressao-de-cancer-cerebral-agressivo-dias-apos-passar-por-tratamento-inovador.jpg\",\n    \"publishedAt\": \"2024-03-15T17:36:34Z\",\n    \"content\": \"Um homem de 72 anos, diagnosticado com um tipo de c\\u00e2ncer cerebral agressivo, teve regress\\u00e3o do tumor em dias ap\\u00f3s passar por um tratamento inovador. O paciente, que n\\u00e3o teve o nome divulgado, recebeu\\u2026 [+3526 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Metropoles.com\"\n    },\n    \"author\": \"Beth\\u00e2nia Nunes\",\n    \"title\": \"CAR-T: Ribeir\\u00e3o Preto inicia teste de terapia celular contra c\\u00e2ncer\",\n    \"description\": \"Os testes com c\\u00e9lulas CAR-T ser\\u00e3o feitos com 81 pacientes com leucemia linfoide aguda de c\\u00e9lulas B e linfoma n\\u00e3o Hodgkin de c\\u00e9lulas B\",\n    \"url\": \"https://www.metropoles.com/saude/cancer-comeca-estudo-car-t-ribeirao-preto\",\n    \"urlToImage\": \"https://uploads.metropoles.com/wp-content/uploads/2023/09/01193121/cancer-sangue.jpg\",\n    \"publishedAt\": \"2024-03-15T13:00:51Z\",\n    \"content\": \"Come\\u00e7a nesta sexta-feira (15/3) a sele\\u00e7\\u00e3o dos pacientes interessados em participar do estudo cl\\u00ednico sobre o tratamento de leucemia e linfoma com a terapia celular CAR-T Cell em Ribeir\\u00e3o Preto, inter\\u2026 [+2704 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Infosalus.com\"\n    },\n    \"author\": null,\n    \"title\": \"Logran resultados espectaculares en pacientes con glioblastoma con terapia celular\",\n    \"description\": \"Un proyecto colaborativo para llevar la promesa de la terapia celular a pacientes con una forma mortal de c\\u00e1ncer cerebral ha mostrado resultados espectaculares entre los primeros pacientes que recibieron el nuevo tratamiento.\",\n    \"url\": \"https://www.infosalus.com/farmacia/noticia-logran-resultados-espectaculares-pacientes-glioblastoma-terapia-celular-20240314074348.html\",\n    \"urlToImage\": \"https://img.europapress.es/fotoweb/fotonoticia_20240314074348_1200.jpg\",\n    \"publishedAt\": \"2024-03-14T06:43:48Z\",\n    \"content\": \"MADRID, 14 Mar. (EUROPA PRESS) - \\r\\n Un proyecto colaborativo para llevar la promesa de la terapia celular a pacientes con una forma mortal de c\\u00e1ncer cerebral ha mostrado resultados espectaculares ent\\u2026 [+4470 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Terra.com.br\"\n    },\n    \"author\": \"DINO\",\n    \"title\": \"Terapia celular vira esperan\\u00e7a para pacientes com c\\u00e2ncer\",\n    \"description\": \"A cura definitiva contra o c\\u00e2ncer \\u00e9 um desafio que mobiliza a ci\\u00eancia em todo o mundo. Somente ...\",\n    \"url\": \"https://www.terra.com.br/noticias/terapia-celular-vira-esperanca-para-pacientes-com-cancer,a79bfad4e8bff956d4ec1298d8a526b4n4qekh33.html\",\n    \"urlToImage\": \"https://p2.trrsf.com/image/fget/cf/1200/630/middle/images.terra.com/2024/03/19/1140999615-eb42214f-a6bb-4443-89b3-47fc71c6c253.jpeg\",\n    \"publishedAt\": \"2024-03-19T13:57:18Z\",\n    \"content\": \"A cura definitiva contra o c\\u00e2ncer \\u00e9 um desafio que mobiliza a ci\\u00eancia em todo o mundo. Somente os casos de leucemia, por exemplo, alcan\\u00e7aram cerca de 475 mil pessoas em todo o mundo em 2020. Os dados\\u2026 [+2173 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Europapress.es\"\n    },\n    \"author\": null,\n    \"title\": \"El HUCA realiza en un a\\u00f1o cinco tratamientos con c\\u00e9lulas CART a pacientes con c\\u00e1ncer y pron\\u00f3stico muy adverso\",\n    \"description\": \"El Hospital Universitario central de Asturias (HUCA) ha realizado desde el pasado abril cinco terapias con c\\u00e9lulas CAR-T a pacientes con linfomas difusos de c\\u00e9lulas grandes B refractario, un c\\u00e1ncer de un tipo de gl\\u00f3bulos blancos (los linfocitos B) que no hab\\u00ed\\u2026\",\n    \"url\": \"https://www.europapress.es/asturias/noticia-huca-realiza-ano-cinco-tratamientos-celulas-cart-pacientes-cancer-pronostico-muy-adverso-20240319174425.html\",\n    \"urlToImage\": \"https://img.europapress.es/fotoweb/fotonoticia_20240319174425_1200.jpg\",\n    \"publishedAt\": \"2024-03-19T16:44:25Z\",\n    \"content\": \"OVIEDO, 19 Mar. (EUROPA PRESS) - \\r\\n El Hospital Universitario central de Asturias (HUCA) ha realizado desde el pasado abril cinco terapias con c\\u00e9lulas CAR-T a pacientes con linfomas difusos de c\\u00e9lula\\u2026 [+2351 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Www.abc.es\"\n    },\n    \"author\": \"(abc)\",\n    \"title\": \"La terapia Car-T llega a los pacientes con tumores cerebrales agresivos\",\n    \"description\": \"Un ensayo pionero de terapia con c\\u00e9lulas CAR-T ha ofrecido resultados prometedores para el tratamiento del glioblastoma, un tumor cerebral muy agresivo. Realizado por investigadores del Instituto City of Hope (EE.UU.) el trabajo, publicado en ' Nature Medicin\\u2026\",\n    \"url\": \"https://www.abc.es/salud/enfermedades/terapia-cart-llega-pacientes-tumores-cerebrales-agresivos-20240308161800-nt.html\",\n    \"urlToImage\": \"https://s3.abcstatics.com/abc/www/multimedia/salud/2024/03/08/cart-t-U68317732823ivN-1024x512@diario_abc.jpg\",\n    \"publishedAt\": \"2024-03-08T15:18:00Z\",\n    \"content\": \"Un ensayo pionero de terapia con c\\u00e9lulas CAR-T ha ofrecido resultados prometedores para el tratamiento del glioblastoma, un tumor cerebral muy agresivo.\\r\\nRealizado por investigadores del Instituto Ci\\u2026 [+124 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Dino.com.br\"\n    },\n    \"author\": null,\n    \"title\": \"Terapia celular vira esperan\\u00e7a para pacientes com c\\u00e2ncer\",\n    \"description\": \"No Brasil, leucemia deve alcan\\u00e7ar cerca de 11,5 mil pessoas a cada ano at\\u00e9 2025\",\n    \"url\": \"https://www.dino.com.br/releases/terapia-celular-vira-esperanca-para-pacientes-com-cancer-dino890301923131\",\n    \"urlToImage\": \"https://s2-valor.glbimg.com/Ta9gWnRUlXB5_2qnejD3Nmzr1uc=/1200x/smart/filters:cover():strip_icc()/i.s3.glbimg.com/v1/AUTH_63b422c2caee4269b8b34177e8876b93/internal_photos/bs/2024/R/h/aFRJQjRgAvcp1Dl7EOZQ/eb42214f-a6bb-4443-89b3-47fc71c6c253.jpeg\",\n    \"publishedAt\": \"2024-03-19T10:53:36Z\",\n    \"content\": \"A cura definitiva contra o c\\u00e2ncer \\u00e9 um desafio que mobiliza a ci\\u00eancia em todo o mundo. Somente os casos de leucemia, por exemplo, alcan\\u00e7aram cerca de 475 mil pessoas em todo o mundo em 2020. Os dados\\u2026 [+2019 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Www.abc.es\"\n    },\n    \"author\": \"(abc)\",\n    \"title\": \"Miguel \\u00c1ngel Perales: \\u00abHe visto resultados inimaginables contra el c\\u00e1ncer\\u00bb\",\n    \"description\": \"De padre espa\\u00f1ol y madre inglesa, Miguel \\u00c1ngel Perales habla un perfecto castellano pero con un acento que delata su infancia en Bruselas, donde naci\\u00f3, y los 32 a\\u00f1os que lleva ejerciendo la medicina en Estados Unidos. Primero investigando en VIH en Boston y d\\u2026\",\n    \"url\": \"https://www.abc.es/sociedad/miguel-angel-perales-visto-resultados-inimaginables-cancer-20240318043619-nt.html\",\n    \"urlToImage\": \"https://s1.abcstatics.com/abc/www/multimedia/sociedad/2024/03/15/perales1-U04072117083jMn-1024x512@diario_abc.JPG\",\n    \"publishedAt\": \"2024-03-18T03:36:20Z\",\n    \"content\": \"De padre espa\\u00f1ol y madre inglesa, Miguel \\u00c1ngel Perales habla un perfecto castellano pero con un acento que delata su infancia en Bruselas, donde naci\\u00f3, y los 32 a\\u00f1os que lleva ejerciendo la medicina \\u2026 [+102 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Elespanol.com\"\n    },\n    \"author\": \"Marcos Dom\\u00ednguez\",\n    \"title\": \"Los tumores s\\u00f3lidos, en la diana de la terapia celular: la clave contra el c\\u00e1ncer que tard\\u00f3 40 a\\u00f1os en llegar\",\n    \"description\": \"Estados Unidos acaba de aprobar el primer tratamiento basado en linfocitos infiltrantes del tumor, dirigido al melanoma metast\\u00e1sico.\",\n    \"url\": \"https://www.elespanol.com/ciencia/salud/20240324/tumores-solidos-diana-terapia-celular-clave-cancer-tardo-anos-llegar/841916252_0.html\",\n    \"urlToImage\": \"https://s1.elespanol.com/2024/03/22/ciencia/salud/841926596_240963154_1706x960.jpg\",\n    \"publishedAt\": \"2024-03-24T01:36:50Z\",\n    \"content\": \"Durante su estancia en EEUU hace ya m\\u00e1s de 30 a\\u00f1os, Jos\\u00e9 Mar\\u00eda Moraleda\\u00a0recuerda que su principal funci\\u00f3n m\\u00e1s all\\u00e1 de ver pacientes, claro consist\\u00eda en conseguir multiplicar linfocitos en el laborato\\u2026 [+8275 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Eldiario.es\"\n    },\n    \"author\": \"Daniel S\\u00e1nchez Caballero\",\n    \"title\": \"Dami\\u00e1n Garc\\u00eda Olmo, investigador: \\\"Las terapias avanzadas son la gran esperanza para las enfermedades sin cura conocida\\\"\",\n    \"description\": \"\\\"Las terapias avanzadas son una esperanza muy grande para las enfermedades que no tienen cura conocida. Cada vez se abren m\\u00e1s campos y posibilidades que pueden cambiar el mundo del medicamento. Estoy pensando, por ejemplo, en la producci\\u00f3n de \\u00f3rganos para los\\u2026\",\n    \"url\": \"https://www.eldiario.es/sociedad/damian-garcia-olmo-investigador-terapias-avanzadas-son-gran-esperanza-enfermedades-cura-conocida_1_11212303.html\",\n    \"urlToImage\": \"https://static.eldiario.es/clip/753bcc0c-e7d1-4d99-a479-d91d51fc95e6_facebook-watermarked-aspect-ratio_default_0.jpg\",\n    \"publishedAt\": \"2024-03-14T21:22:22Z\",\n    \"content\": \"\\u201cLas terapias avanzadas son una esperanza muy grande para las enfermedades que no tienen cura conocida. Cada vez se abren m\\u00e1s campos y posibilidades que pueden cambiar el mundo del medicamento. Estoy\\u2026 [+775 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Www.abc.es\"\n    },\n    \"author\": \"(abc)\",\n    \"title\": \"\\u00bfCu\\u00e1l es la enfermedad m\\u00e1s dif\\u00edcil de curar?\",\n    \"description\": \"Para quien sufre una enfermedad larga, la suya siempre ser\\u00e1 la m\\u00e1s dif\\u00edcil de curar . Aunque en realidad hay algunas enfermedades objetivamente incurables: solo podemos tratar sus s\\u00edntomas para que dejen de causar sufrimiento y avancen lo m\\u00e1s lentamente posib\\u2026\",\n    \"url\": \"https://www.abc.es/salud/enfermedades/enfermedad-dificil-curar-20240322144814-nt.html\",\n    \"urlToImage\": \"https://s2.abcstatics.com/abc/www/multimedia/salud/2024/03/22/enfermedad-dificil-curar-U68744425251ohb-1024x512@diario_abc.JPG\",\n    \"publishedAt\": \"2024-03-22T13:48:15Z\",\n    \"content\": \"Para quien sufre una enfermedad larga, la suya siempre ser\\u00e1 la m\\u00e1s dif\\u00edcil de curar. Aunque en realidad hay algunas enfermedades objetivamente incurables: solo podemos tratar sus s\\u00edntomas para que de\\u2026 [+122 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Scientific American\"\n    },\n    \"author\": \"Carol Cardona, Michelle Kromm\",\n    \"title\": \"CRISPR Will Likely Not Solve Bird Flu\",\n    \"description\": \"New research shows that CRISPR, the gene editing technique, could make chickens more resistant to bird flu. But its use raises many ethical and scientific issues\",\n    \"url\": \"https://www.scientificamerican.com/article/crispr-will-likely-not-solve-bird-flu/\",\n    \"urlToImage\": \"https://static.scientificamerican.com/dam/m/3795530f84bdb20b/original/2R0WMHN.jpg?w=1200\",\n    \"publishedAt\": \"2024-03-11T13:00:00Z\",\n    \"content\": \"Recently, a group of scientists announced a breakthrough approach to combat Highly Pathogenic Avian Influenza (bird flu or avian flu), a severe illness of birds that has killed millions of chickens w\\u2026 [+6192 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"heise online\"\n    },\n    \"author\": \"Thomas Hoffmann\",\n    \"title\": \"Erste genomeditierte Babys: Forscher setzt umstrittene Arbeit fort\",\n    \"description\": \"Vom Gef\\u00e4ngnis zur\\u00fcck ins Labor: He Jiankui,  der Forscher, der weltweit f\\u00fcr Schlagzeilen sorgte, will Genom-Editing bei menschlichen Embryonen fortsetzen.\",\n    \"url\": \"https://www.heise.de/news/Erste-genomeditierte-Babys-Forscher-setzt-umstrittene-Arbeit-fort-9672027.html\",\n    \"urlToImage\": \"https://heise.cloudimg.io/bound/1200x1200/q85.png-lossy-85.webp-lossy-85.foil1/_www-heise-de_/imgs/18/4/5/6/5/6/8/5/jkpaper2-b7c5c37e75a02fba-722892ab323d97c1.webp\",\n    \"publishedAt\": \"2024-04-01T12:00:00Z\",\n    \"content\": \"Inhaltsverzeichnis\\r\\nDer chinesische Forscher He Jiankui, der 2018 durch die Ank\\u00fcndigung der Geburt der ersten genomeditierten Babys weltweit f\\u00fcr Schlagzeilen sorgte, hat seine Forschung wieder aufgen\\u2026 [+2958 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Phys.Org\"\n    },\n    \"author\": \"Zhang Nannan\",\n    \"title\": \"CRISPRlnc: New lncRNA-specific SgRNA design method proposed\",\n    \"description\": \"Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts. Currently, CRISPR/Cas9 is a promising RNA-guided genome editing technology consisting of a Cas9 nuclease and a single-guide RNA (sgRNA). Considering the significant differences between lncRNAs\\u2026\",\n    \"url\": \"https://phys.org/news/2024-03-crisprlnc-lncrna-specific-sgrna-method.html\",\n    \"urlToImage\": \"https://scx2.b-cdn.net/gfx/news/2024/crisprlnc-new-lncrna-s.jpg\",\n    \"publishedAt\": \"2024-03-07T16:32:02Z\",\n    \"content\": \"Long non-coding RNAs (lncRNAs) are non-protein-coding transcripts. Currently, CRISPR/Cas9 is a promising RNA-guided genome editing technology consisting of a Cas9 nuclease and a single-guide RNA (sgR\\u2026 [+2762 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Lbl.gov\"\n    },\n    \"author\": \"akovner\",\n    \"title\": \"It's Hearty, It's Meaty, It's Mold\",\n    \"description\": \"Did you know fungi naturally produce all the ingredients needed for a cruelty-free meat substitute? Our scientists are exploring how tuning the genomes of mushrooms and molds can transform these food sources into gourmet, nutrient-packed meals made with minim\\u2026\",\n    \"url\": \"https://newscenter.lbl.gov/2024/03/14/its-hearty-its-meaty-its-mold/\",\n    \"urlToImage\": \"https://newscenter.lbl.gov/wp-content/uploads/2024/03/ak-bio-edited.jpg\",\n    \"publishedAt\": \"2024-03-14T22:43:14Z\",\n    \"content\": \"With animal-free dairy products and convincing vegetarian meat substitutes already on the market, its easy to see how biotechnology can change the food industry. Advances in genetic engineering are a\\u2026 [+4286 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"heise online\"\n    },\n    \"author\": \"Marie-Claire Koch\",\n    \"title\": \"Geneditierte Schweineniere in lebenden Menschen transplantiert\",\n    \"description\": \"Chirurgen am Massachusetts General Hospital haben erstmals einem lebenden Menschen eine Schweineniere transplantiert. Der 62-J\\u00e4hrige erhole sich gut, hei\\u00dft es.\",\n    \"url\": \"https://www.heise.de/news/Geneditierte-Schweineniere-in-lebenden-Menschen-transplantiert-9664509.html\",\n    \"urlToImage\": \"https://heise.cloudimg.io/bound/1200x1200/q85.png-lossy-85.webp-lossy-85.foil1/_www-heise-de_/imgs/18/4/5/6/1/7/3/2/d41586-024-00879-y_26889516-065f90d8d486afec.webp\",\n    \"publishedAt\": \"2024-03-25T07:33:00Z\",\n    \"content\": \"Ein Team aus Chirurgen am Massachusetts General Hospital (MGH) hat erstmals eine Schweineniere erfolgreich einem lebenden Menschen transplantiert. Derzeit erhole sich der 62-j\\u00e4hrige Patient gut von d\\u2026 [+2552 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Le HuffPost\"\n    },\n    \"author\": \"Jules Castagni\\u00e9, Benjamin Houry\",\n    \"title\": \"Ce champignon g\\u00e9n\\u00e9tiquement modifi\\u00e9 a tout d\\u2019un (vrai) steak\",\n    \"description\": \"Les chercheurs ont utilis\\u00e9 les ciseaux de manipulation g\\u00e9n\\u00e9tique CRISPR-Cas9\\u00a0pour r\\u00e9aliser leur recette.\",\n    \"url\": \"https://www.huffingtonpost.fr/science/video/ce-champignon-genetiquement-modifie-a-tout-d-un-vrai-steak_232233.html\",\n    \"urlToImage\": \"https://huffpost-focus.sirius.press/2024/04/05/0/0/1920/1080/1820/1023/75/0/f2b10e3_1712310046078-minia-base.jpg\",\n    \"publishedAt\": \"2024-04-06T06:00:18Z\",\n    \"content\": \"La lecture de ce contenu est susceptible dentra\\u00eener un d\\u00e9p\\u00f4t de cookies de la part de lop\\u00e9rateur tiers qui lh\\u00e9berge. Compte-tenu des choix que vous avez exprim\\u00e9s en mati\\u00e8re de d\\u00e9p\\u00f4t de cookies, nous \\u2026 [+2017 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Microsiervos.com\"\n    },\n    \"author\": \"wicho@microsiervos.com (Wicho)\",\n    \"title\": \"Un paciente estadounidense recibe el trasplante de un ri\\u00f1\\u00f3n de cerdo por primera vez\",\n    \"description\": \"Cirujanos del MGH durante la operaci\\u00f3n \\u2013 MGH\\n\\nHace unos d\\u00edas el Hospital General de Massachusetts (MGH) anunciaba el trasplante de un ri\\u00f1\\u00f3n de cerdo modificado gen\\u00e9ticamente a un paciente de 62 a\\u00f1os con enfermedad renal terminal. Es la primera vez que se hace\\u2026\",\n    \"url\": \"https://www.microsiervos.com/archivo/ciencia/trasplante-rinon-cerdo.html\",\n    \"urlToImage\": \"https://img.microsiervos.com/images2024/CirujanosXenotrasplanteRinonCerdo.webp\",\n    \"publishedAt\": \"2024-03-23T19:00:00Z\",\n    \"content\": \"Por @Wicho 23 de Marzo de 2024\\r\\nCirujanos del MGH durante la operaci\\u00f3n MGH\\r\\nHace unos d\\u00edas el Hospital General de Massachusetts (MGH) anunciaba el trasplante de un ri\\u00f1\\u00f3n de cerdo modificado gen\\u00e9ticam\\u2026 [+1709 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Jandan.net\"\n    },\n    \"author\": \"BALI\",\n    \"title\": \"\\u4f2f\\u514b\\u5229\\u79d1\\u5b66\\u5bb6\\u7528\\u57fa\\u56e0\\u7f16\\u8f91\\u6280\\u672f\\u6539\\u9020\\u771f\\u83cc\\uff0c\\u505a\\u6210\\u53e3\\u611f\\u903c\\u771f\\u7684\\u201c\\u771f\\u83cc\\u8089\\u997c\\u201d\",\n    \"description\": \"\\u8272\\u6cfd\\u8bf1\\u4eba\\uff0c\\u53e3\\u611f\\u53ef\\u5851\",\n    \"url\": \"http://jandan.net/p/115932\",\n    \"urlToImage\": null,\n    \"publishedAt\": \"2024-03-16T23:05:16Z\",\n    \"content\": \"BALI @ 2024.03.17 , 07:05\\r\\n0\\r\\n Vayu Hill-Maini () \\r\\n Hill-Maini \\u00b7 (Jay Keasling) \\r\\nHill-Maini CRISPR-Cas9 Hill-Maini ()\\r\\n()\\r\\nHill-Maini Hill-Maini \\r\\n() CRISPR-Cas9 \\r\\n \\u00b7 (Jay Keasling) \\r\\nHill-Maini Ke\\u2026 [+153 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Science Daily\"\n    },\n    \"author\": null,\n    \"title\": \"It's hearty, it's meaty, it's mold\",\n    \"description\": \"Scientists are exploring how tuning the genomes of mushrooms and molds can transform these food sources into gourmet, nutrient-packed meals made with minimal processing and a light environmental footprint.\",\n    \"url\": \"https://www.sciencedaily.com/releases/2024/03/240314122135.htm\",\n    \"urlToImage\": \"https://www.sciencedaily.com/images/scidaily-icon.png\",\n    \"publishedAt\": \"2024-03-14T16:21:35Z\",\n    \"content\": \"With animal-free dairy products and convincing vegetarian meat substitutes already on the market, it's easy to see how biotechnology can change the food industry. Advances in genetic engineering are \\u2026 [+6545 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Phys.Org\"\n    },\n    \"author\": \"Science X\",\n    \"title\": \"Messenger RNAs with multiple 'tails' could lead to more effective therapeutics, say res\n\n*** WARNING: max output size exceeded, skipping output. ***\n\noleucel in Second- and Third-Line Treatment of Multiple Myeloma\",\n    \"description\": \"IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma           PR Newswire             SHANGHAI   and   NANJING   ,   China   and   SAN JOSE, Calif.     ,     March 29, 2024     /PR...\",\n    \"url\": \"https://www.investorsobserver.com/news/qm-pr/5400199748104440\",\n    \"urlToImage\": \"https://s3.amazonaws.com/images.investorsobserver.com/io-logo-800x450.jpg\",\n    \"publishedAt\": \"2024-03-29T05:20:00Z\",\n    \"content\": \"SHANGHAI\\r\\nand\\r\\nNANJING\\r\\n,\\r\\nChina\\r\\nand\\r\\nSAN JOSE, Calif.\\r\\n,\\r\\nMarch 29, 2024\\r\\n/PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innov\\u2026 [+5600 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"ETF Daily News\"\n    },\n    \"author\": \"MarketBeat News\",\n    \"title\": \"Reviewing Allogene Therapeutics (NASDAQ:ALLO) & Tenaya Therapeutics (NASDAQ:TNYA)\",\n    \"description\": \"Allogene Therapeutics (NASDAQ:ALLO \\u2013 Get Free Report) and Tenaya Therapeutics (NASDAQ:TNYA \\u2013 Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, divi\\u2026\",\n    \"url\": \"https://www.etfdailynews.com/2024/03/08/reviewing-allogene-therapeutics-nasdaqallo-tenaya-therapeutics-nasdaqtnya/\",\n    \"urlToImage\": \"https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/tenaya-therapeutics-inc-logo-1200x675.jpg?v=20210813072008&w=240&h=240&zc=2\",\n    \"publishedAt\": \"2024-03-08T07:32:42Z\",\n    \"content\": \"Allogene Therapeutics (NASDAQ:ALLO \\u2013 Get Free Report) and Tenaya Therapeutics (NASDAQ:TNYA \\u2013 Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the \\u2026 [+6299 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Marketscreener.com\"\n    },\n    \"author\": null,\n    \"title\": \"Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award\",\n    \"description\": \"(marketscreener.com) \\n\\nWEXFORD, Pa., April 2, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. , a biopharmaceutical company developing innovative cell therapy platforms for cancer, is pleased to acknowledge and congratulate Professor Alexander Deiter\\u2026\",\n    \"url\": \"https://www.marketscreener.com/quote/stock/COEPTIS-THERAPEUTICS-HOLD-146105655/news/Coeptis-Therapeutics-Congratulates-Alexander-Deiters-Professor-at-the-University-of-Pittsburgh-on-46339014/\",\n    \"urlToImage\": \"https://www.marketscreener.com/images/twitter_MS_fdblanc.png\",\n    \"publishedAt\": \"2024-04-02T12:48:09Z\",\n    \"content\": \"WEXFORD, Pa., April 2, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (\\\"Coeptis\\\" or \\\"the Company\\\"), a biopharmaceutical company developing innovative cell therapy platforms f\\u2026 [+6874 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Shtfplan.com\"\n    },\n    \"author\": \"Mac Slavo\",\n    \"title\": \"Linoleic Acid: A key Contributing Factor In Rising Cancer Rates\",\n    \"description\": \"Global cancer incidence is increasing, particularly among those under 50, with a notable rise in breast, uterine, prostate, lung, colorectal, pancreatic, and stomach cancers, with early-onset breast cancer incidence climbing by 3.8% annually between 2016 and \\u2026\",\n    \"url\": \"https://www.shtfplan.com/headline-news/linoleic-acid-a-key-contributing-factor-in-rising-cancer-rates\",\n    \"urlToImage\": \"https://www.shtfplan.com/wp-content/uploads/2024/04/seedoil.jpg\",\n    \"publishedAt\": \"2024-04-03T12:30:10Z\",\n    \"content\": \"This article was originally published by Rhoda Wilson at The Daily Expos\\u00e9.\\r\\nGlobal cancer incidence is increasing, particularly among those under 50, with a notable rise in breast, uterine, prostate,\\u2026 [+19462 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Marketscreener.com\"\n    },\n    \"author\": null,\n    \"title\": \"Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference\",\n    \"description\": \"(marketscreener.com) \\nCartesian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 23rd Annual Needham Virtual \\u2026\",\n    \"url\": \"https://www.marketscreener.com/quote/stock/CARTESIAN-THERAPEUTICS-IN-28734714/news/Cartesian-Therapeutics-to-Participate-in-the-23rd-Annual-Needham-Virtual-Healthcare-Conference-46362142/\",\n    \"urlToImage\": \"https://www.marketscreener.com/images/twitter_MS_fdblanc.png\",\n    \"publishedAt\": \"2024-04-04T11:31:05Z\",\n    \"content\": \"Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to p\\u2026 [+1178 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"GlobeNewswire\"\n    },\n    \"author\": \"Mustang Bio, Inc.\",\n    \"title\": \"Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights\",\n    \"description\": \"WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (\\u201cMustang\\u201d or the \\u201cCompany\\u201d) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today\\u2019s medical breakthroughs in cell and gene therapies into potential cures\\u2026\",\n    \"url\": \"https://www.globenewswire.com/news-release/2024/03/11/2844140/0/en/Mustang-Bio-Reports-Full-Year-2023-Financial-Results-and-Recent-Corporate-Highlights.html\",\n    \"urlToImage\": \"https://ml.globenewswire.com/Resource/Download/75bd19b8-c298-4600-953e-f9b6215c043c\",\n    \"publishedAt\": \"2024-03-11T20:05:00Z\",\n    \"content\": \"WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang or the Company) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakt\\u2026 [+23425 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Marketscreener.com\"\n    },\n    \"author\": null,\n    \"title\": \"Poseida Therapeutics : Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 - Form 8-K\",\n    \"description\": \"(marketscreener.com) \\n Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023\\n \\n \\n Lead asset P-BCMA-ALLO1 Phase 1 clinical trial data presented at ASH 2023 demonstrated 82% ORR and favorable emerging safety and \\u2026\",\n    \"url\": \"https://www.marketscreener.com/quote/stock/POSEIDA-THERAPEUTICS-INC-109519711/news/Poseida-Therapeutics-Provides-Updates-and-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2-46123044/\",\n    \"urlToImage\": \"https://www.marketscreener.com/images/twitter_MS_fdblanc.png\",\n    \"publishedAt\": \"2024-03-07T21:08:16Z\",\n    \"content\": \"Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023\\r\\nLead asset P-BCMA-ALLO1 Phase 1 clinical trial data presented at ASH 2023 demonstrated 82% ORR a\\u2026 [+21471 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"GlobeNewswire\"\n    },\n    \"author\": \"PolTREG S.A.\",\n    \"title\": \"PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab\",\n    \"description\": \"Gda\\u0144sk, Poland \\u2013 4 April 2024 \\u2013 PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has published data in International Immunopharmacology whic\\u2026\",\n    \"url\": \"https://www.globenewswire.com/news-release/2024/04/04/2857466/0/en/PolTREG-identifies-promising-efficacy-biomarker-for-Type-1-diabetes-in-patients-treated-with-its-Treg-therapy-in-combination-with-rituximab.html\",\n    \"urlToImage\": \"https://ml-eu.globenewswire.com/Resource/Download/95d1b8cc-053b-4b21-977e-bcac1cb1e8c4\",\n    \"publishedAt\": \"2024-04-04T05:00:00Z\",\n    \"content\": \"<ul><li>New biomarker may facilitate monitoring T1D patients health</li><li>Increase in PD-1+ T-cells correlated with therapeutic response and less insulin use</li></ul>Gdask, Poland 4 April 2024 Pol\\u2026 [+5899 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Marketscreener.com\"\n    },\n    \"author\": null,\n    \"title\": \"Autolus Therapeutics announces publication in Blood Cancer Journal\",\n    \"description\": \"(marketscreener.com) LONDON, March 11, 2024 -- Autolus Therapeutics plc\\u202f, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled \\u2018Dual T-cell constant \\u03b2\\u2026\",\n    \"url\": \"https://www.marketscreener.com/quote/stock/AUTOLUS-THERAPEUTICS-PLC-44336207/news/Autolus-Therapeutics-announces-publication-in-Blood-Cancer-Journal-46139372/\",\n    \"urlToImage\": \"https://www.marketscreener.com/images/twitter_MS_fdblanc.png\",\n    \"publishedAt\": \"2024-03-11T11:03:02Z\",\n    \"content\": \"LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a\\u2026 [+5565 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"GlobeNewswire\"\n    },\n    \"author\": \"Immix Biopharma, Inc.\",\n    \"title\": \"Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial\",\n    \"description\": \"LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (\\u201cImmixBio\\u201d, \\u201cCompany\\u201d, \\u201cWe\\u201d or \\u201cUs\\u201d or \\u201cIMMX\\u201d), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, t\\u2026\",\n    \"url\": \"https://www.globenewswire.com/news-release/2024/03/20/2849459/0/en/Immix-Biopharma-Announces-Major-Comprehensive-Cancer-Center-as-Lead-Site-for-NXC-201-AL-Amyloidosis-Clinical-Trial.html\",\n    \"urlToImage\": \"https://ml.globenewswire.com/Resource/Download/b46d5687-65de-44df-81d5-e36f2665d8e7\",\n    \"publishedAt\": \"2024-03-20T13:46:00Z\",\n    \"content\": \"LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (ImmixBio, Company, We or Us or IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies \\u2026 [+4870 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Investing.com\"\n    },\n    \"author\": \"Investing.com\",\n    \"title\": \"TC BioPharm eyes expansion with CAR-NK technology LOI\",\n    \"description\": \"TC BioPharm eyes expansion with CAR-NK technology LOI\",\n    \"url\": \"https://www.investing.com/news/company-news/tc-biopharm-eyes-expansion-with-carnk-technology-loi-93CH-3365852\",\n    \"urlToImage\": \"https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg\",\n    \"publishedAt\": \"2024-04-04T13:10:21Z\",\n    \"content\": \"EDINBURGH - TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a biotech firm specializing in gamma-delta T cell therapies, has announced its intention to acquire new assets to expand its therapeutic platfor\\u2026 [+4161 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": \"abc-news\",\n      \"name\": \"ABC News\"\n    },\n    \"author\": \"LAURAN NEERGAARD AP medical writer\",\n    \"title\": \"A new strategy to attack aggressive brain cancer shrank tumors in two early tests\",\n    \"description\": \"Researchers revved up immune cells that shrank an extremely aggressive type of brain tumor when tested in a handful of patients\",\n    \"url\": \"https://abcnews.go.com/Health/wireStory/new-strategy-attack-aggressive-brain-cancer-shrank-tumors-108095511\",\n    \"urlToImage\": \"https://i.abcnewsfe.com/a/de63aeca-3ac2-41a1-be8c-65b244fdf855/wirestory_4cc8a6dd8ae016ec1c4500c48a0fe1af_16x9.jpg?w=1600\",\n    \"publishedAt\": \"2024-03-13T21:10:42Z\",\n    \"content\": \"WASHINGTON -- A new strategy to fight an extremely aggressive type of brain tumor showed promise in a pair of experiments with a handful of patients.\\r\\nScientists took patients own immune cells and tu\\u2026 [+3081 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"GlobeNewswire\"\n    },\n    \"author\": \"Research and Markets\",\n    \"title\": \"Cancer Immunotherapy Market Research 2024: The Race for the Cures - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer including Executive and Consultant Guides\",\n    \"description\": \"Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The \\\"Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2023 to 2027\\\" report has b\\u2026\",\n    \"url\": \"https://www.globenewswire.com/news-release/2024/03/13/2845630/28124/en/Cancer-Immunotherapy-Market-Research-2024-The-Race-for-the-Cures-Forecasts-for-Immuno-Oncology-Therapeutics-by-Therapy-Cancer-and-Customer-including-Executive-and-Consultant-Guides.html\",\n    \"urlToImage\": \"https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7\",\n    \"publishedAt\": \"2024-03-13T15:26:00Z\",\n    \"content\": \"Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The \\\"Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including\\u2026 [+7031 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Marketscreener.com\"\n    },\n    \"author\": null,\n    \"title\": \"Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)\",\n    \"description\": \"(marketscreener.com) Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALLThe US marketing application is under review with a Prescription Drug User Fee Act target action date of November 16, 2024 LONDON, April 02, 2024 \\u2026\",\n    \"url\": \"https://www.marketscreener.com/quote/stock/AUTOLUS-THERAPEUTICS-PLC-44336207/news/Autolus-Therapeutics-announces-acceptance-of-Marketing-Authorization-Application-MAA-by-the-Europe-46337663/\",\n    \"urlToImage\": \"https://www.marketscreener.com/images/twitter_MS_fdblanc.png\",\n    \"publishedAt\": \"2024-04-02T11:02:08Z\",\n    \"content\": \"<ul><li>Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALL</li><li>The US marketing application is under review with a Prescription Drug User Fee Act (PDUFA)\\u2026 [+6315 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Marketscreener.com\"\n    },\n    \"author\": null,\n    \"title\": \"Syncona : Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)\",\n    \"description\": \"(marketscreener.com) \\n Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALL\\n \\n \\n The US marketing application is under review with a Prescription Drug User Fee Act target action date of November 16, 2024\\n \\n \\n Autolus Th\\u2026\",\n    \"url\": \"https://www.marketscreener.com/quote/stock/SYNCONA-LIMITED-11814171/news/Syncona-Autolus-Therapeutics-announces-acceptance-of-Marketing-Authorization-Application-MAA-by-46339457/\",\n    \"urlToImage\": \"https://www.marketscreener.com/images/twitter_MS_fdblanc.png\",\n    \"publishedAt\": \"2024-04-02T13:14:56Z\",\n    \"content\": \"Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALL\\r\\nThe US marketing application is under review with a Prescription Drug User Fee Act (PDUFA) target action \\u2026 [+6260 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Marketscreener.com\"\n    },\n    \"author\": null,\n    \"title\": \"U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy\",\n    \"description\": \"(marketscreener.com) \\nAbecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile\\n\\n\\nExpanded approval brings this pers\\u2026\",\n    \"url\": \"https://www.marketscreener.com/quote/stock/BRISTOL-MYERS-SQUIBB-COMP-11877/news/U-S-FDA-Approves-Bristol-Myers-Squibb-and-2seventy-bio-s-Abecma-for-Triple-Class-Exposed-Relapsed-46373132/\",\n    \"urlToImage\": \"https://www.marketscreener.com/images/twitter_MS_fdnoir.png\",\n    \"publishedAt\": \"2024-04-05T13:08:06Z\",\n    \"content\": \"Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profil\\u2026 [+33713 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"ETF Daily News\"\n    },\n    \"author\": \"MarketBeat News\",\n    \"title\": \"Critical Analysis: Caribou Biosciences (NASDAQ:CRBU) vs. Organovo (NASDAQ:ONVO)\",\n    \"description\": \"Caribou Biosciences (NASDAQ:CRBU \\u2013 Get Free Report) and Organovo (NASDAQ:ONVO \\u2013 Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional\\u2026\",\n    \"url\": \"https://www.etfdailynews.com/2024/03/07/critical-analysis-caribou-biosciences-nasdaqcrbu-vs-organovo-nasdaqonvo/\",\n    \"urlToImage\": \"https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/organovo-holdings-inc-logo-1200x675.png&w=240&h=240&zc=2\",\n    \"publishedAt\": \"2024-03-07T06:58:44Z\",\n    \"content\": \"Caribou Biosciences (NASDAQ:CRBU \\u2013 Get Free Report) and Organovo (NASDAQ:ONVO \\u2013 Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two busine\\u2026 [+4869 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"InvestorsObserver\"\n    },\n    \"author\": \"InvestorsObserver\",\n    \"title\": \"U.S. FDA Approves Bristol Myers Squibb's Breyanzi\\u00ae as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)\",\n    \"description\": \"Breyanzi   offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had no standard of care             In TRANSCEND CLL 0...\",\n    \"url\": \"https://www.investorsobserver.com/news/qm-pr/7678246767471497\",\n    \"urlToImage\": \"https://s3.amazonaws.com/images.investorsobserver.com/io-logo-800x450.jpg\",\n    \"publishedAt\": \"2024-03-14T21:35:00Z\",\n    \"content\": \"News HomeMentioned in this article\\r\\nBreyanzi\\r\\noffers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory\\u2026 [+27702 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"ETF Daily News\"\n    },\n    \"author\": \"MarketBeat News\",\n    \"title\": \"Mustang Bio (NASDAQ:MBIO) versus Inhibitor Therapeutics (OTCMKTS:INTI) Head-To-Head Contrast\",\n    \"description\": \"Inhibitor Therapeutics (OTCMKTS:INTI \\u2013 Get Free Report) and Mustang Bio (NASDAQ:MBIO \\u2013 Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional o\\u2026\",\n    \"url\": \"https://www.etfdailynews.com/2024/03/11/mustang-bio-nasdaqmbio-versus-inhibitor-therapeutics-otcmktsinti-head-to-head-contrast/\",\n    \"urlToImage\": \"https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/mustang-bio-logo-1200x675.jpg&w=240&h=240&zc=2\",\n    \"publishedAt\": \"2024-03-11T05:16:41Z\",\n    \"content\": \"Inhibitor Therapeutics (OTCMKTS:INTI \\u2013 Get Free Report) and Mustang Bio (NASDAQ:MBIO \\u2013 Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the t\\u2026 [+4970 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"ETF Daily News\"\n    },\n    \"author\": \"MarketBeat News\",\n    \"title\": \"Aura Biosciences (NASDAQ:AURA) versus Caribou Biosciences (NASDAQ:CRBU) Financial Contrast\",\n    \"description\": \"Aura Biosciences (NASDAQ:AURA \\u2013 Get Free Report) and Caribou Biosciences (NASDAQ:CRBU \\u2013 Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnin\\u2026\",\n    \"url\": \"https://www.etfdailynews.com/2024/03/27/aura-biosciences-nasdaqaura-versus-caribou-biosciences-nasdaqcrbu-financial-contrast/\",\n    \"urlToImage\": \"https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/caribou-biosciences-inc-logo-1200x675.png?v=20221209112145&w=240&h=240&zc=2\",\n    \"publishedAt\": \"2024-03-27T06:48:49Z\",\n    \"content\": \"Aura Biosciences (NASDAQ:AURA \\u2013 Get Free Report) and Caribou Biosciences (NASDAQ:CRBU \\u2013 Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the tw\\u2026 [+5020 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Marketscreener.com\"\n    },\n    \"author\": null,\n    \"title\": \"CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for\\u00a0Future Precision Therapies\",\n    \"description\": \"(marketscreener.com) SINGAPORE, March 18, 2024 -- CytoMed Therapeutics Limited , a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel blood donor-derived, cell-based allogeneic therapies for the treat\\u2026\",\n    \"url\": \"https://www.marketscreener.com/quote/stock/CYTOMED-THERAPEUTICS-LIMI-153435036/news/CytoMed-Therapeutics-to-Launch-Complimentary-Cell-Banking-for-Qualified-Shareholders-for-Future-Pre-46219463/\",\n    \"urlToImage\": \"https://www.marketscreener.com/images/twitter_MS_fdnoir.png\",\n    \"publishedAt\": \"2024-03-18T10:02:01Z\",\n    \"content\": \"SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (CytoMed or Company), a Singapore-based biopharmaceutical company focused on harnessing its proprietary techn\\u2026 [+10995 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Investing.com\"\n    },\n    \"author\": \"Investing.com\",\n    \"title\": \"CARVYKTI \\u00ae is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy\",\n    \"description\": \"CARVYKTI \\u00ae is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy\",\n    \"url\": \"https://www.investing.com/news/press-releases/carvykti--is-the-first-and-only-bcmatargeted-treatment-approved-by-the-us-fda-for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy-93CH-3368367\",\n    \"urlToImage\": \"https://i-invdn-com.investing.com/news/news_headline_rolled_69x52._800x533_L_1419494221.jpg\",\n    \"publishedAt\": \"2024-04-06T03:32:05Z\",\n    \"content\": \"Expanded indication for this one-time infusion will provide more patients with a potential period away from their multiple myeloma treatment as early as first relapse\\r\\nApproval is based on results fr\\u2026 [+36148 chars]\"\n  },\n  {\n    \"source\": {\n      \"id\": null,\n      \"name\": \"Marketscreener.com\"\n    },\n    \"author\": null,\n    \"title\": \"Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial\",\n    \"description\": \"(marketscreener.com) LOS ANGELES, CA, March 20, 2024 -- Immix Biopharma, Inc. , a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced Memorial Sloan Kettering Cancer Center as l\\u2026\",\n    \"url\": \"https://www.marketscreener.com/quote/stock/IMMIX-BIOPHARMA-INC-130728145/news/Immix-Biopharma-Announces-Major-Comprehensive-Cancer-Center-as-Lead-Site-for-NXC-201-AL-Amyloidosis-46242801/\",\n    \"urlToImage\": \"https://www.marketscreener.com/images/twitter_MS_fdnoir.png\",\n    \"publishedAt\": \"2024-03-20T13:47:01Z\",\n    \"content\": \"LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (ImmixBio, Company, We or Us or IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies \\u2026 [+4875 chars]\"\n  }\n]\n"
     ]
    }
   ],
   "source": [
    "from pyspark.sql import SparkSession\n",
    "from pyspark.sql.functions import col, when, isnull, date_format\n",
    "from pyspark.sql.types import StructType, StructField, StringType, DateType\n",
    "from pyspark.sql.utils import AnalysisException\n",
    "import requests, json, time\n",
    "\n",
    "\n",
    "spark = SparkSession.builder \\\n",
    "    .appName(\"Tratamento de Dados\") \\\n",
    "    .getOrCreate()\n",
    "\n",
    "def buscar_news():\n",
    "    api_key = '4f8fba63c2ec4291a45c702ea3858120'\n",
    "    exemplos = [\"Terapia Gênica\", \"Terapia Celular CAR-T\", \"CRISPR-Cas9\", \"Gene therapy\", \"CAR-T cell therapy\"]\n",
    "    all_articles = []\n",
    "    for exemplo in exemplos:\n",
    "        url = f'https://newsapi.org/v2/everything?q={exemplo}&apiKey={api_key}'\n",
    "        response = requests.get(url)\n",
    "        data = response.json().get('articles', []) if response.ok else []\n",
    "        all_articles.extend(data)\n",
    "    return all_articles\n",
    "\n",
    "schema = StructType([\n",
    "    StructField(\"source\", StructType([\n",
    "        StructField(\"id\", StringType(), True),\n",
    "        StructField(\"name\", StringType(), True)\n",
    "    ]), True),\n",
    "    StructField(\"author\", StringType(), True),\n",
    "    StructField(\"title\", StringType(), True),\n",
    "    StructField(\"description\", StringType(), True),\n",
    "    StructField(\"url\", StringType(), True),\n",
    "    StructField(\"urlToImage\", StringType(), True),\n",
    "    StructField(\"publishedAt\", StringType(), True),\n",
    "    StructField(\"content\", StringType(), True)\n",
    "])\n",
    "\n",
    "def requisitar_news():\n",
    "    articles = buscar_news()\n",
    "    if articles:\n",
    "        df = spark.createDataFrame(articles, schema=schema)\n",
    "        return df\n",
    "    else:\n",
    "        return None\n",
    "\n",
    "resultado = buscar_news()\n",
    "print(json.dumps(resultado, indent=2))\n",
    "\n",
    "#df.write.mode(\"overwrite\").saveAsTable(\"noticias_bancodedados\") #IMPORTANTE"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "61cc12a1-7128-4340-bcec-2729dc5b5f6f",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "from pyspark.sql.utils import AnalysisException\n",
    "\n",
    "def atualizar_base_dados(df, spark):\n",
    "    \"\"\"\n",
    "    Atualiza a base de dados Delta Lake com novas notícias.\n",
    "    \n",
    "    :param df: DataFrame contendo as novas notícias a serem adicionadas.\n",
    "    :param spark: SparkSession.\n",
    "    :return: DataFrame atualizado.\n",
    "    \"\"\"\n",
    "    try:\n",
    "        # Tenta ler o arquivo Delta existente\n",
    "        base_dados = spark.read.format(\"delta\").load(\"dbfs:/user/hive/warehouse/noticias_bancodedados\")\n",
    "    except AnalysisException as e:\n",
    "        print(\"Erro ao acessar Delta Lake:\", str(e))\n",
    "        # Se houver um erro ao acessar Delta Lake, assume que é a primeira vez e usa o DataFrame fornecido\n",
    "        print(\"Criando uma nova tabela Delta com os dados fornecidos.\")\n",
    "        base_dados = df\n",
    "        base_dados.write.mode(\"overwrite\").saveAsTable(\"noticias_bancodedados\")\n",
    "        return base_dados\n",
    "    \n",
    "    try:\n",
    "        # Verifica se há novas notícias comparando o número de registros\n",
    "        novas_noticias_count = df.join(base_dados, [\"url\"], \"left_anti\").count()\n",
    "        \n",
    "        # Adiciona novas notícias\n",
    "        if novas_noticias_count > 0:\n",
    "            base_dados = base_dados.union(df)\n",
    "            print(\"Novas notícias adicionadas à tabela de Noticias.\")\n",
    "        else:\n",
    "            print(\"Nenhuma nova notícia para adicionar à tabela Noticias.\")\n",
    "    except AnalysisException as e:\n",
    "        print(\"Erro ao atualizar tabela Delta Lake:\", str(e))\n",
    "        return base_dados\n",
    "    \n",
    "    try:\n",
    "        # Escreve o DataFrame de volta para a tabela Delta\n",
    "        base_dados.write.mode(\"overwrite\").format(\"delta\").save(\"dbfs:/user/hive/warehouse/noticias_bancodedados\")\n",
    "        print(\"\\nDados atualizados com sucesso!\")\n",
    "    except AnalysisException as e:\n",
    "        print(\"Erro ao atualizar tabela Delta Lake:\", str(e))\n",
    "    \n",
    "    return base_dados\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "f151595c-f1cd-42ea-bf6c-554d898729f0",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Nenhuma nova notícia para adicionar à tabela Noticias.\n\nDados atualizados com sucesso!\n+-------------------+--------------------+--------------------+--------------------+--------------------+-----------+--------------------+\n|        source_name|              author|               title|         description|                 url|publishedAt|             content|\n+-------------------+--------------------+--------------------+--------------------+--------------------+-----------+--------------------+\n|         Uol.com.br|     Renata Turbiani|          Sem Titulo|Rejany Machado Pe...|https://www.uol.c...| 10/03/2024|Só que dessa vez ...|\n|         Uol.com.br|      Agência Fapesp|Pesquisador da US...|Os testes com cél...|https://gizmodo.u...| 15/03/2024|Texto: André Juli...|\n|Olhardigital.com.br|Leandro Costa Cri...|SP dá início a es...|81 pacientes deve...|https://olhardigi...| 26/03/2024|Já havíamos falad...|\n|Olhardigital.com.br|Alessandro Di Lor...|CAR-T Cell: estud...|USP vai dar iníci...|https://olhardigi...| 14/03/2024|Um importante pas...|\n|         Www.abc.es|               (abc)|La terapia celula...|Una nueva terapia...|https://www.abc.e...| 13/03/2024|Una nueva terapia...|\n|     Metropoles.com|      Bethânia Nunes|Terapia CAR-T mod...|Atualmente, a ter...|https://www.metro...| 15/03/2024|Um homem de 72 an...|\n|     Metropoles.com|      Bethânia Nunes|CAR-T: Ribeirão P...|Os testes com cél...|https://www.metro...| 15/03/2024|Começa nesta sext...|\n|       Terra.com.br|                DINO|Terapia celular v...|A cura definitiva...|https://www.terra...| 19/03/2024|A cura definitiva...|\n|         Www.abc.es|               (abc)|La terapia Car-T ...|Un ensayo pionero...|https://www.abc.e...| 08/03/2024|Un ensayo pionero...|\n|         Www.abc.es|               (abc)|Miguel Ángel Pera...|De padre español ...|https://www.abc.e...| 18/03/2024|De padre español ...|\n|      Elespanol.com|    Marcos Domínguez|Los tumores sólid...|Estados Unidos ac...|https://www.elesp...| 24/03/2024|Durante su estanc...|\n|        Eldiario.es|Daniel Sánchez Ca...|Damián García Olm...|\"Las terapias ava...|https://www.eldia...| 14/03/2024|“Las terapias ava...|\n|         Www.abc.es|               (abc)|¿Cuál es la enfer...|Para quien sufre ...|https://www.abc.e...| 22/03/2024|Para quien sufre ...|\n|Scientific American|Carol Cardona, Mi...|CRISPR Will Likel...|New research show...|https://www.scien...| 11/03/2024|Recently, a group...|\n|       heise online|     Thomas Hoffmann|Erste genomeditie...|Vom Gefängnis zur...|https://www.heise...| 01/04/2024|Inhaltsverzeichni...|\n|           Phys.Org|        Zhang Nannan|CRISPRlnc: New ln...|Long non-coding R...|https://phys.org/...| 07/03/2024|Long non-coding R...|\n|            Lbl.gov|             akovner|It's Hearty, It's...|Did you know fung...|https://newscente...| 14/03/2024|With animal-free ...|\n|       heise online|   Marie-Claire Koch|Geneditierte Schw...|Chirurgen am Mass...|https://www.heise...| 25/03/2024|Ein Team aus Chir...|\n|        Le HuffPost|Jules Castagnié, ...|Ce champignon gén...|Les chercheurs on...|https://www.huffi...| 06/04/2024|La lecture de ce ...|\n|   Microsiervos.com|wicho@microsiervo...|Un paciente estad...|Cirujanos del MGH...|https://www.micro...| 23/03/2024|Por @Wicho 23 de ...|\n+-------------------+--------------------+--------------------+--------------------+--------------------+-----------+--------------------+\nonly showing top 20 rows\n\n"
     ]
    }
   ],
   "source": [
    "# Função para tratar os dados do DataFrame\n",
    "def tratar_source(df):\n",
    "    # Requisita as notícias e armazena no DataFrame 'df'\n",
    "    df = requisitar_news()\n",
    "    \n",
    "    # Verifica se há dados no DataFrame\n",
    "    if df:\n",
    "        # Cria uma nova coluna 'source_name' com base nos valores de 'source.id' e 'source.name'\n",
    "        df = df.withColumn(\"source_name\", when(col(\"source.id\").isNull(), col(\"source.name\")).otherwise(col(\"source.id\")))\n",
    "        \n",
    "        # Remove a coluna 'source' do DataFrame\n",
    "        df = df.drop(\"source\")\n",
    "        \n",
    "        # Remove linhas com valores nulos na coluna 'author'\n",
    "        df = df.dropna(subset=[\"author\"])\n",
    "        \n",
    "        # Substitui valores nulos na coluna 'author' por 'Desconhecido'\n",
    "        df = df.withColumn(\"author\", when(col(\"author\").isNull(), \"Desconhecido\").otherwise(col(\"author\")))\n",
    "        \n",
    "        # Substitui valores nulos na coluna 'title' por 'Sem Titulo'\n",
    "        df = df.withColumn(\"title\", when(col(\"title\").isNull(), \"Sem Titulo\").otherwise(col(\"title\")))\n",
    "        \n",
    "        # Formata a coluna 'publishedAt' para o formato \"dd/MM/yyyy\"\n",
    "        df = df.withColumn(\"publishedAt\", date_format(df[\"publishedAt\"], \"dd/MM/yyyy\"))\n",
    "        \n",
    "        # Remove as colunas '_id' e 'urlToImage' do DataFrame\n",
    "        df = df.drop(\"_id\", \"urlToImage\")\n",
    "        \n",
    "        # Seleciona as colunas desejadas, incluindo 'source_name' como a primeira coluna\n",
    "        columns = [\"source_name\"] + [col_name for col_name in df.columns if col_name != \"source_name\"]\n",
    "        df = df.select(columns)\n",
    "        \n",
    "        # Chama a função para atualizar a base de dados com os dados tratados\n",
    "        df = atualizar_base_dados(df, spark)\n",
    "\n",
    "    return df\n",
    "\n",
    "# Chama a função para tratar os dados\n",
    "df = tratar_source(df)\n",
    "\n",
    "df.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "9ab98252-563f-43e3-9cd3-232738dc6419",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Iniciando: Processo de atualização.\nAtualmente o banco de dados tem 247 linhas.\nO número de linhas não aumentou.\nRepetindo...\nIniciando: Processo de atualização.\nAtualmente o banco de dados tem 247 linhas.\nO número de linhas não aumentou.\nRepetindo...\n"
     ]
    },
    {
     "output_type": "display_data",
     "data": {
      "text/html": [
       "<style scoped>\n",
       "  .ansiout {\n",
       "    display: block;\n",
       "    unicode-bidi: embed;\n",
       "    white-space: pre-wrap;\n",
       "    word-wrap: break-word;\n",
       "    word-break: break-all;\n",
       "    font-family: \"Menlo\", \"Monaco\", \"Consolas\", \"Ubuntu Mono\", \"Source Code Pro\", monospace;\n",
       "    font-size: 13px;\n",
       "    color: #555;\n",
       "    margin-left: 4px;\n",
       "    line-height: 19px;\n",
       "  }\n",
       "</style>"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "arguments": {},
       "data": "",
       "errorSummary": "Cancelled",
       "errorTraceType": "html",
       "metadata": {},
       "type": "ipynbError"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import time\n",
    "\n",
    "while True:\n",
    "    # Consulta para contar o número de linhas no banco de dados\n",
    "    rows_before = spark.sql(\"SELECT COUNT(*) as count FROM noticias_bancodedados\").collect()[0]['count']\n",
    "    \n",
    "    print(\"Iniciando: Processo de atualização.\")\n",
    "    print(f\"Atualmente o banco de dados tem {rows_before} notícias.\")\n",
    "    \n",
    "    # Busca as novas notícias\n",
    "    buscar_news()\n",
    "    \n",
    "    # Requisita as novas notícias e armazena no DataFrame 'df'\n",
    "    df = requisitar_news()\n",
    "    \n",
    "    # Chama a função para tratar os dados\n",
    "    df = tratar_source(df)\n",
    "    \n",
    "    # Atualiza a base de dados com os dados tratados\n",
    "    df = atualizar_base_dados(df, spark)\n",
    "    \n",
    "    # Consulta para contar o número de linhas após a atualização\n",
    "    rows_after = spark.sql(\"SELECT COUNT(*) as count FROM noticias_bancodedados\").collect()[0]['count']\n",
    "    \n",
    "    # Verifica se o número de linhas aumentou\n",
    "    if rows_after > rows_before:\n",
    "        print(\"O número de notícias aumentou!\")\n",
    "    else:\n",
    "        print(\"O número de notícias não aumentou.\")\n",
    "    \n",
    "    print(\"Repetindo...\")\n",
    "    # Espera 60 minutos\n",
    "    time.sleep(60 * 1)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "ed739961-7a1c-4388-ac5b-2ce1e5fd7c93",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+-------------------+--------------------+--------------------+--------------------+--------------------+-----------+--------------------+\n|        source_name|              author|               title|         description|                 url|publishedAt|             content|\n+-------------------+--------------------+--------------------+--------------------+--------------------+-----------+--------------------+\n|         Uol.com.br|     Renata Turbiani|          Sem Titulo|Rejany Machado Pe...|https://www.uol.c...| 10/03/2024|Só que dessa vez ...|\n|         Uol.com.br|      Agência Fapesp|Pesquisador da US...|Os testes com cél...|https://gizmodo.u...| 15/03/2024|Texto: André Juli...|\n|Olhardigital.com.br|Leandro Costa Cri...|SP dá início a es...|81 pacientes deve...|https://olhardigi...| 26/03/2024|Já havíamos falad...|\n|Olhardigital.com.br|Alessandro Di Lor...|CAR-T Cell: estud...|USP vai dar iníci...|https://olhardigi...| 14/03/2024|Um importante pas...|\n|         Www.abc.es|               (abc)|La terapia celula...|Una nueva terapia...|https://www.abc.e...| 13/03/2024|Una nueva terapia...|\n|     Metropoles.com|      Bethânia Nunes|Terapia CAR-T mod...|Atualmente, a ter...|https://www.metro...| 15/03/2024|Um homem de 72 an...|\n|     Metropoles.com|      Bethânia Nunes|CAR-T: Ribeirão P...|Os testes com cél...|https://www.metro...| 15/03/2024|Começa nesta sext...|\n|       Terra.com.br|                DINO|Terapia celular v...|A cura definitiva...|https://www.terra...| 19/03/2024|A cura definitiva...|\n|         Www.abc.es|               (abc)|La terapia Car-T ...|Un ensayo pionero...|https://www.abc.e...| 08/03/2024|Un ensayo pionero...|\n|         Www.abc.es|               (abc)|Miguel Ángel Pera...|De padre español ...|https://www.abc.e...| 18/03/2024|De padre español ...|\n+-------------------+--------------------+--------------------+--------------------+--------------------+-----------+--------------------+\n\n"
     ]
    }
   ],
   "source": [
    "spark.sql(\"SELECT * FROM noticias_bancodedados LIMIT 10\").show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "06d9838f-b18c-4656-a19a-abb8d53484cd",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+---+---+----+----------+\n|dia|mes| ano|quantidade|\n+---+---+----+----------+\n| 21|  3|2024|        24|\n| 20|  3|2024|        17|\n| 15|  3|2024|        17|\n| 14|  3|2024|        17|\n|  2|  4|2024|        15|\n|  4|  4|2024|        14|\n| 28|  3|2024|        12|\n| 13|  3|2024|        11|\n| 27|  3|2024|        10|\n|  1|  4|2024|         9|\n| 18|  3|2024|         9|\n| 25|  3|2024|         8|\n| 19|  3|2024|         7|\n| 22|  3|2024|         7|\n|  7|  3|2024|         7|\n| 29|  3|2024|         7|\n| 12|  3|2024|         6|\n| 30|  3|2024|         6|\n|  8|  3|2024|         5|\n| 16|  3|2024|         5|\n+---+---+----+----------+\nonly showing top 20 rows\n\n"
     ]
    }
   ],
   "source": [
    "quantidades_data = spark.sql(\"\"\"\n",
    "    SELECT DAY(to_date(publishedAt, 'dd/MM/yyyy')) AS dia, \n",
    "           MONTH(to_date(publishedAt, 'dd/MM/yyyy')) AS mes, \n",
    "           YEAR(to_date(publishedAt, 'dd/MM/yyyy')) AS ano,\n",
    "           COUNT(*) AS quantidade \n",
    "    FROM noticias_bancodedados \n",
    "    GROUP BY DAY(to_date(publishedAt, 'dd/MM/yyyy')), \n",
    "             MONTH(to_date(publishedAt, 'dd/MM/yyyy')), \n",
    "             YEAR(to_date(publishedAt, 'dd/MM/yyyy'))\n",
    "    ORDER BY quantidade DESC\n",
    "\"\"\")\n",
    "\n",
    "\n",
    "quantidades_data.show()\n",
    "\n",
    "quantidades_data = quantidades_data.toJSON().collect()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "6e1e2878-548a-4974-b86f-f5cdd589bd71",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+--------------------+--------------------+----------+\n|         source_name|              author|quantidade|\n+--------------------+--------------------+----------+\n|      ETF Daily News|     MarketBeat News|        13|\n|       Investing.com|       Investing.com|         9|\n|   InvestorsObserver|   InvestorsObserver|         6|\n|              Forbes|William A. Haselt...|         5|\n|       GlobeNewswire|Research and Markets|         5|\n|            Phys.Org|           Science X|         5|\n|     Singularity Hub|          Shelly Fan|         5|\n|          Biztoc.com|        benzinga.com|         5|\n|          Www.abc.es|               (abc)|         4|\n|Bengreenfieldlife...|support@bengreenf...|         4|\n|               WebMD|https://www.faceb...|         4|\n|                  rt|RT en Español\\n ,...|         3|\n|        ars-technica|           Beth Mole|         3|\n|    Sputnikglobe.com|   Chimauchem  Nwosu|         3|\n|       Investing.com|             Reuters|         3|\n|       GlobeNewswire|   Mustang Bio, Inc.|         3|\n|         Asriran.com|    info@asriran.com|         2|\n|      Metropoles.com|      Bethânia Nunes|         2|\n|    The Boston Globe|   Jonathan Saltzman|         2|\n|            Phys.Org|        Zhang Nannan|         2|\n+--------------------+--------------------+----------+\nonly showing top 20 rows\n\n"
     ]
    }
   ],
   "source": [
    "quantidades_fonte_autor = spark.sql(\"\"\"\n",
    "    SELECT source_name, \n",
    "           author, \n",
    "           COUNT(*) AS quantidade \n",
    "    FROM noticias_bancodedados \n",
    "    GROUP BY source_name, author\n",
    "    ORDER BY quantidade DESC\n",
    "\"\"\")\n",
    "\n",
    "quantidades_fonte_autor.show()\n",
    "\n",
    "quantidades_fonte_autor = quantidades_fonte_autor.toJSON().collect()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "2dc73f96-9a30-4f58-9584-a451c4704bf6",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+------------+----------+\n|     palavra|quantidade|\n+------------+----------+\n|      chars]|       237|\n|        with|        33|\n|        that|        33|\n|        have|        30|\n|       March|        24|\n|     therapy|        24|\n|        cell|        22|\n|Therapeutics|        21|\n|        gene|        18|\n|        from|        17|\n|     Report)|        17|\n|        been|        17|\n|        Free|        17|\n|      CRISPR|        17|\n|       first|        16|\n|      cancer|        16|\n|    patients|        15|\n|        this|        15|\n|        2024|        14|\n|        will|        14|\n+------------+----------+\nonly showing top 20 rows\n\n"
     ]
    }
   ],
   "source": [
    "rank_palavras = spark.sql(\"\"\"\n",
    "    SELECT palavra, COUNT(*) AS quantidade\n",
    "    FROM (\n",
    "        SELECT EXPLODE(SPLIT(content, ' ')) AS palavra\n",
    "        FROM noticias_bancodedados\n",
    "    ) palavras\n",
    "    WHERE LENGTH(palavra) > 3\n",
    "    GROUP BY palavra\n",
    "    ORDER BY quantidade DESC\n",
    "\"\"\")\n",
    "\n",
    "rank_palavras.show()\n",
    "\n",
    "json_rank_palavras = rank_palavras.toJSON().collect() #Ideia para como armazenar na API\n",
    "\n",
    "#print(json_rank_palavras)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "0e63b260-2a76-4666-b42d-e613314e792d",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Python interpreter will be restarted.\nCollecting kafka-python\n  Using cached kafka_python-2.0.2-py2.py3-none-any.whl (246 kB)\nInstalling collected packages: kafka-python\nSuccessfully installed kafka-python-2.0.2\nPython interpreter will be restarted.\n"
     ]
    }
   ],
   "source": [
    "pip install kafka-python"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "ab8597b2-a445-4441-8140-215eca9c5804",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "from kafka import KafkaProducer, KafkaConsumer\n",
    "import json"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "45bd2693-1131-47f9-b163-e31e1d356465",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "\n",
    "producer = KafkaProducer(bootstrap_servers=[\"localhost:9092\"])\n",
    "\n",
    "topicos = [\"rank_palavras\", \"quantidades_data\", \"quantidades_fonte_autor\"]\n",
    "\n",
    "# Dados JSON para cada tópico\n",
    "json_rank_palavras = json_rank_palavras\n",
    "json_quantidades_data = quantidades_data\n",
    "json_quantidades_fonte_autor = quantidades_fonte_autor\n",
    "\n",
    "# Enviar dados para cada tópico\n",
    "for topico, json_data in zip(topicos, [json_rank_palavras, json_quantidades_data, json_quantidades_fonte_autor]):\n",
    "    mensagem = json.dumps(json_data).encode('utf-8')\n",
    "    producer.send(topico, mensagem)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "4b15a63d-c940-4b6f-9c64-5fdc50c859a4",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\"{\\\"palavra\\\":\\\"chars]\\\",\\\"quantidade\\\":237}\", \"{\\\"palavra\\\":\\\"with\\\",\\\"quantidade\\\":33}\", \"{\\\"palavra\\\":\\\"that\\\",\\\"quantidade\\\":33}\", \"{\\\"palavra\\\":\\\"have\\\",\\\"quantidade\\\":30}\", \"{\\\"palavra\\\":\\\"March\\\",\\\"quantidade\\\":24}\", \"{\\\"palavra\\\":\\\"therapy\\\",\\\"quantidade\\\":24}\", \"{\\\"palavra\\\":\\\"cell\\\",\\\"quantidade\\\":22}\", \"{\\\"palavra\\\":\\\"Therapeutics\\\",\\\"quantidade\\\":21}\", \"{\\\"palavra\\\":\\\"gene\\\",\\\"quantidade\\\":18}\", \"{\\\"palavra\\\":\\\"from\\\",\\\"quantidade\\\":17}\", \"{\\\"palavra\\\":\\\"Report)\\\",\\\"quantidade\\\":17}\", \"{\\\"palavra\\\":\\\"been\\\",\\\"quantidade\\\":17}\", \"{\\\"palavra\\\":\\\"Free\\\",\\\"quantidade\\\":17}\", \"{\\\"palavra\\\":\\\"CRISPR\\\",\\\"quantidade\\\":17}\", \"{\\\"palavra\\\":\\\"first\\\",\\\"quantidade\\\":16}\", \"{\\\"palavra\\\":\\\"cancer\\\",\\\"quantidade\\\":16}\", \"{\\\"palavra\\\":\\\"patients\\\",\\\"quantidade\\\":15}\", \"{\\\"palavra\\\":\\\"this\\\",\\\"quantidade\\\":15}\", \"{\\\"palavra\\\":\\\"2024\\\",\\\"quantidade\\\":14}\", \"{\\\"palavra\\\":\\\"will\\\",\\\"quantidade\\\":14}\", \"{\\\"palavra\\\":\\\"treatment\\\",\\\"quantidade\\\":14}\", \"{\\\"palavra\\\":\\\"brain\\\",\\\"quantidade\\\":14}\", \"{\\\"palavra\\\":\\\"This\\\",\\\"quantidade\\\":13}\", \"{\\\"palavra\\\":\\\"which\\\",\\\"quantidade\\\":13}\", \"{\\\"palavra\\\":\\\"General\\\",\\\"quantidade\\\":12}\", \"{\\\"palavra\\\":\\\"into\\\",\\\"quantidade\\\":12}\", \"{\\\"palavra\\\":\\\"according\\\",\\\"quantidade\\\":11}\", \"{\\\"palavra\\\":\\\"NEWSWIRE)\\\",\\\"quantidade\\\":11}\", \"{\\\"palavra\\\":\\\"(GLOBE\\\",\\\"quantidade\\\":11}\", \"{\\\"palavra\\\":\\\"company\\\",\\\"quantidade\\\":11}\", \"{\\\"palavra\\\":\\\"your\\\",\\\"quantidade\\\":11}\", \"{\\\"palavra\\\":\\\"like\\\",\\\"quantidade\\\":11}\", \"{\\\"palavra\\\":\\\"shares\\\",\\\"quantidade\\\":10}\", \"{\\\"palavra\\\":\\\".\\\\r\\\\n,\\\",\\\"quantidade\\\":10}\", \"{\\\"palavra\\\":\\\"after\\\",\\\"quantidade\\\":10}\", \"{\\\"palavra\\\":\\\"disease\\\",\\\"quantidade\\\":10}\", \"{\\\"palavra\\\":\\\"aggressive\\\",\\\"quantidade\\\":10}\", \"{\\\"palavra\\\":\\\"modificado\\\",\\\"quantidade\\\":9}\", \"{\\\"palavra\\\":\\\"cells\\\",\\\"quantidade\\\":9}\", \"{\\\"palavra\\\":\\\"(NASDAQ:CRSP\\\",\\\"quantidade\\\":9}\", \"{\\\"palavra\\\":\\\"were\\\",\\\"quantidade\\\":9}\", \"{\\\"palavra\\\":\\\"medical\\\",\\\"quantidade\\\":9}\", \"{\\\"palavra\\\":\\\"genetic\\\",\\\"quantidade\\\":9}\", \"{\\\"palavra\\\":\\\"following\\\",\\\"quantidade\\\":9}\", \"{\\\"palavra\\\":\\\"type\\\",\\\"quantidade\\\":9}\", \"{\\\"palavra\\\":\\\"their\\\",\\\"quantidade\\\":8}\", \"{\\\"palavra\\\":\\\"ri\\u00f1\\u00f3n\\\",\\\"quantidade\\\":8}\", \"{\\\"palavra\\\":\\\"Hospital\\\",\\\"quantidade\\\":8}\", \"{\\\"palavra\\\":\\\"sold\\\",\\\"quantidade\\\":8}\", \"{\\\"palavra\\\":\\\"cerdo\\\",\\\"quantidade\\\":8}\", \"{\\\"palavra\\\":\\\"article\\\",\\\"quantidade\\\":8}\", \"{\\\"palavra\\\":\\\"study\\\",\\\"quantidade\\\":8}\", \"{\\\"palavra\\\":\\\"years\\\",\\\"quantidade\\\":8}\", \"{\\\"palavra\\\":\\\"U.S.\\\",\\\"quantidade\\\":8}\", \"{\\\"palavra\\\":\\\"Massachusetts\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"este\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"most\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"mundo\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"last\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"Science\\u00a0X's\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"process\\\\r\\\\nand\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"reviewed\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"ensuring\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"highlighted\\\\r\\\\nthe\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"while\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"content's\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"\\\\r\\\\neditorial\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"policies.\\\\r\\\\nEditors\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"credibility:\\\\r\\\\nfact-checked\\\\r\\u2026\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"attributes\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"those\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"promise\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"immune\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"therapies\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"clinical\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"cancer,\\\",\\\"quantidade\\\":7}\", \"{\\\"palavra\\\":\\\"stock\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"gen\\u00e9ticamente\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"system\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"week\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"part\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"said\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"Cas9,\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"para\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"CAR-T\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"Hill-Maini\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"tumor\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"announced\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"treatments\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"when\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"what\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"Gene\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"Inc.\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"form\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"Therapy\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"$4.25\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"T-cell\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"therapy,\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"blood\\\",\\\"quantidade\\\":6}\", \"{\\\"palavra\\\":\\\"transaction\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"jueves\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"(2024)\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"recent\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"create\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"Citation:\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"regenerative\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"trasplante\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"Dublin,\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"revealed\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"primera\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"Cas9\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"news\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"CRISPR/Cas9\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"breakthrough\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"world\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"&amp;\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"tratamento\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"Food\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"medicine\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"they\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"approved\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"drug\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"Drug\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"pain\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"Thursday\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"Administration\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"every\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"Pharmaceuticals\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"one-time\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"million,\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"strategy\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"early\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"biopharmaceutical\\\",\\\"quantidade\\\":5}\", \"{\\\"palavra\\\":\\\"Nobel\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"Market\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"progression\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"a\\u00f1os\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"report\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"Regenerative\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"digits\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"story\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"paciente\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"PLoS\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"1999,\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"only\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"series\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"current\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"defined\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"Nature\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"anunciado\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"sickle\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"Medicine.\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"once\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"worlds\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"first,\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"2018\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"types\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"gene-edited\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"science\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"breast\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"reports\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"latest\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"procedure\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"kidney\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"surgeons\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"heard\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"transplanted\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"giorno\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"stories\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"News\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"gravi\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"living\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"already\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"terapia\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"Cell\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"often\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"flooded\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"relationships,\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"felt\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"took\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"long\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"work.\\\\r\\\\nAnd\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"moment\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"about\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"then\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"school,\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"called\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"agonizing\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"infusion\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"April\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"Cancer\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"approval\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"(NASDAQ:\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"through\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"Therapeutics,\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"Biosciences\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"trial\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"human\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"Phase\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"both\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"fight\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"companies,\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"small-cap\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"showed\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"Bristol\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"Myers\\\",\\\"quantidade\\\":4}\", \"{\\\"palavra\\\":\\\"lista\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"hombre\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"could\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"ap\\u00f3s\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"option\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"research\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Chinese\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"average\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"successful\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"during\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"ciencia\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"again\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Research\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"possible\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Estados\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Technology\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"primer\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"price\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"saranno\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"traded\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"change\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"working\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Jiankui\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"background\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Boston\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"using\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"technology\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"group\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"created\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"CRISPR-Cas9,\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"molto\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"est\\u00e1\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"2022\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"potrebbe\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"found\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"deep\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"como\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Journal\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"cura\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Prize\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"back\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"CRISPR-Cas9\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"than\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"linfoma\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"California,\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"leucemia\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"glioblastoma,\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"developing\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"biotechnology\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"estudo\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"University\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"President\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"more\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"program\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"treat\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Disease\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"team\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"life\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"data\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"potential\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"unit\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"very\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"receiving\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"2024,\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"before\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"expected\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"They\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"news.\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"discovery\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Immediate\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"deadliest\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"weekly\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Rocket\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Orchard\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"granted\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"genes\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"glioblastoma\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"here.\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"(Reuters)\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"expensive\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"digest\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"tumors\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"inbox,\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"priced\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"cells.\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"subscribe\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"InnovationRx\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"2023\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Medicine\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"diagnosed\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"healthcare\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"among\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"clinical-stage\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"extremely\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"stock?\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"IASO\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"(Nasdaq:\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Biosciences,\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"response\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"developing,\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Global\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"therapeutic\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"discovering,\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"JOSE,\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"responses\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"manufacturing\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"biotech\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"2024\\\\r\\\\n/PRNewswire/\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"pair\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"better\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"results\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"added\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"autoimmune\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"concept\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"underway\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"Squibb\\\",\\\"quantidade\\\":3}\", \"{\\\"palavra\\\":\\\"hope\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"embargo,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Services\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"drives\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"render\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Freepik\\\\r\\\\nThis\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"extra\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"industry\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"trasplantar\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"occurred\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"helping\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"interview,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"yaplan\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"olmu\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"gigante\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Review\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"because\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"process\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Biol\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"baardklarn\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"strand\\\\r\\\\nImage\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Management\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"eight\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"insanlar\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"[+6506\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"beat.\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"fatty\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Negli\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"carne\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"HIV'i\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"cient\\u00edficos\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"money\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"disturbing\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"[+2306\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"nuclease\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"h\\u00fccrelerden\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"\\u00e7almada\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"kjpargeter\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"claims-processing\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"pandas\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"\\u00e9xito\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"fields\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"11th.\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"\\\\\\\"Global\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"other\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"enfekte\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"late\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"issued\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"babies\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"missed\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"deitirme\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"laboratuvar\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Model\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"enfermedad\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"scientist\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"genome-edited\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"able\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"seems\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Jiankui,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"bilim\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"just\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"vivo\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"care\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"grupo\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"humano\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"promising\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"looking\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"expanding\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"14\\\\r\\\\nIn\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Zhou\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Shares\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"ayrmay\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"hospital\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"earnings\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"position\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Kulkarni\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Samarth\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"ortamnda\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"times,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"over\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"sign\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"15th.\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"reports.\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Monday,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"amounts,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"pri\\u2026\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"pubblicato\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Investment\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"a\\u00e7klad.\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"implemented\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"\\u00f6d\\u00fcll\\u00fc\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"months,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Medicare\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"adds\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"afectado\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"brains\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Getty\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"quarter,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"rating\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"transplantation\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Friday,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"[+6192\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"jailed\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"human.\\\\r\\\\nNews\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"news,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"videos,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"[+6606\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"data,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Boston,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"umani\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"CRISPR-CAS9\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"human.\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"editing\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"2019\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Internet!\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Sar\\u00e0\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"sicuri\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"cultural\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\".\\\\r\\\\nCRISPR\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"\\\\r\\\\nCRISPR\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"GPS\\u00bb\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"a\\u00f1os,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"food\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"investigadores\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"CRISPR/Cas9,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Nano\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"[+6167\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Check\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Communications\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"esseri\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"xenotransplantation\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"-.\\\\r\\\\n\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"persona\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"hits,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"photos,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"agli\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"media\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"social\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"organi\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"(Hill-Maini)\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"malati\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"[+5965\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"forse\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"(Aspergillus\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"across\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"oryzae)\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"(CRISPR-Cas9)\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"fungi\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"tumors)\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\".\\\\r\\\\n-\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"recibir\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"primeros\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Hospital\\\\r\\\\nIn\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Aspergillus\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"alta\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"(xenotrapianti)\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Nature,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"(basal-like\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"attesa\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"cookies\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"made\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"stories,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"dagli\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"effica\\u2026\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"What\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"break\\u2026\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"ridursi.\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"trapianti\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"casos\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"much\\u2026\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\".\\\\r\\\\n\\\\\\\"\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"animali\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"trending\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"researchers\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"\\u00bb.\\\\r\\\\n\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"also\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"globe\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"effect\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Lifestyle,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"(Jay\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"cerebral\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Science\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"koji\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"esperanza\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"cl\\u00ednico\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"(MGH)\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"nueva\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"actually\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"2012,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"patented\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Impossible\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"c\\u00e2ncer\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"c\\u00e9lulas\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"d\\u00e9p\\u00f4t\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"scientific\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"\\\\r\\\\nHill-Maini\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"people\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Keasling)\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"nesta\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Noble\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Latina.\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"in\\u00edcio\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"introduced\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"todo\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"developers\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Am\\u00e9rica\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"teve\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Para\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"enfermedades\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Patient\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"With\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"Cl\\u00ednicas\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"goes\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"anos,\\\",\\\"quantidade\\\":2}\", \"{\\\"palavra\\\":\\\"several\\\",\\\"quantidade\\\":2}\", \n\n*** WARNING: max output size exceeded, skipping output. ***\n\n, \"{\\\"palavra\\\":\\\"when,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"disclosed\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"treated\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Waves\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"initial\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Funding\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Mass.,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"EDINBURGH\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"30th\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"personalized\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+5899\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+4869\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Pol\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"gamma-delta\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"hedge\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"prostate,\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+5020\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"innov\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Website\\u00a0button\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"wasnt\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"period\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Beau\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"2024\\\\r\\\\nCellectar\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"MBIO),\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"authors\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"busine\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"MB-101\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"away\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"McEleney\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"IMMX),\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"delivered\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Immunotherapy\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Business\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+4602\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"manufacturi\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"treating\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"healthy,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+6346\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"sustained\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"began\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"M&amp;A\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Researchs\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(NASDAQ:TNYA\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"intention\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"IPOs,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"ResearchAndMark\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+5542\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"\\\\\\\"Innovation\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(only\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"refractory\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+7031\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"safety,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Tenaya\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"fully\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+4161\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(OTCMKTS:INTI\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Biden,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"funds\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"serv\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"article\\\\r\\\\nBreyanzi\\\\r\\\\noffers\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"trials\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Biopharma,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"expansion\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"available\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"\\\\\\\"CAR-T\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"ANTLER\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"acquire\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(NASDAQ:ONVO\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"McCain\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Immuno-oncology\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Expos\\u00e9.\\\\r\\\\nGlobal\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"BioPharm\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"busy\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Customer\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(NASDAQ:CLRB)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"lymphoma\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Manufacturing\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"offering.\\\\r\\\\nImmuno-oncology\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"News\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+4970\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"investment?\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+36148\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"translating\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"languages\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"and,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"the\\u00a0Translate\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(NASDAQ:MBIO\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"use</li></ul>Gdask,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"patients'\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+6299\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(Neldaleucel)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Allogene\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"well-tolerated\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"2024\\\\\\\"\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"efficacy\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"cold,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"right:\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Fumi\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"experienced,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"International\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"freepik\\\\r\\\\nThis\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"even\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"leukodystrophy\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"anyone\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"simple.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"\\\\r\\\\nWorking\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+1625\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+135\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"sitcom\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Pest\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"mansion,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"self-funded\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"tests\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(HACs)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Blaese,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Prof.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"evera\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"GLP-1\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"sciences,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"accumulated\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"HIV,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"afflicting\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Changyang\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Bouchard.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"modest\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"press\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"day.\\\\r\\\\nMark\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"buzzwords\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"shrugging\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"platform.RJVA-001\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"cuts\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Kirin\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"mention\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"2024\\\\r\\\\nToday,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"chemotherapy,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"looked\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"coll\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"celebrate\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Laboratory\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"U.S.,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"School\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Department\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+3004\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Company\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"bringing\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"person\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"former\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"researcher\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"headqua\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"price:\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"divide,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+7752\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+4188\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"sixth\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Purge.You\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"infected\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Institute\\\\r\\\\nThis\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"brunch\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"brain.'\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"pioneering\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"\\u2014\\u00a0Scientists\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"left\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+6129\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+4006\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Photographs\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"earn\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Today\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"scissors,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"world.\\\\r\\\\nPharma\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"decide\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"lifetime.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Michael\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"pancreatic\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"youre\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"figure\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+44880\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"findings\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Therapy\\\\r\\\\nImage\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"postdoctoral\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"gotten\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"whose\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"negative\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"The\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"bills\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"brownstone\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"After\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Sichuan\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"jus\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Biotherapy,\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"clone\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"\\\\r\\\\nNicole\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"chromosomes.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Instagram\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Society\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"news:\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"687%\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"candid\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"GV.\\\\r\\\\nGV\\\\r\\\\nAs\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"American\\u00a0animated\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"eliminated\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"\\\\r\\\\nFreepik\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Pennsylvania\\u2019s\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Release:\\\\r\\\\nMarch\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+2111\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Fellow\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"disclosures\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(atidarsagene\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"revolutionize\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Munns\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"NagasakaThey\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"conference\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+4715\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"indicated\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"now,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Wong-Staal,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"candidate\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Jaworski\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Association\\\\r\\\\nThe\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+1997\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"annual\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Season\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"finally\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"together\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"want\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"eighth\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Brooklyn\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"development.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"matters.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"entrepreneur-in-residence\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"way,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"scoring\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+3414\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"evolution,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"replicate\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"halfway\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"S.L.\\\\r\\\\nThis\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+2543\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+2121\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Switching\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"much\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"GUTS\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Flossie\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"never\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"celebrated\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"There\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"chromosomes\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"thera\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"X-shaped\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"technology.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"list\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"poignant\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"PHILADELPHIA\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"virus.\\u201dFlossie\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Timing\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"French\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"menu\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"surprise\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"1990.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"M.D.\\\\r\\\\nNational\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+2020\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+1926\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"gone\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+7306\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"2024Actress\\u00a0Olivia\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"surely\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"reasons\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"clean\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"tightly\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"structures\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"gene-editing\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Rejuva\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"cell\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"by\\u00a0Loren\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"level,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Promotion\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"call\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Jimmy\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"lungs\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Gong\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"someone\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Gaudelli,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"subsidiary\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"triple-digit\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"companyOrchard\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Culver,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"messy\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Fractyl\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"mic\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"commonly\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+289\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"doctors\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+7966\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"familiar\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"tricky\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"deceptively\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"costs\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Actuary\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Financial,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Studios\\\\r\\\\nRocket\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"protect\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Kenneth\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"'chemo\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+5207\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"good\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"fatal\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Crafted\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Monday\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"preclinical\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"gunk.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"higher.A\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+7467\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Actuaries.\\\\r\\\\ngetty\\\\r\\\\nAsk\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"event\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Perelman\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Mehb\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"scientist,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"installment\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Prize-winning\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"edition,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"right\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"communit\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"youve\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Biotherapy,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Anderson,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Miami\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Center\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"simple\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"side\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"autotemcel),\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"waning\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"blueprint\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Gain,\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Crispr\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"wound\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+3951\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"manufacturer\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"infants\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"started\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+7091\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"keep\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Exchange\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"expel\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"successfully\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"GLP-1s\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"held\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"boost.The\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Sleeper\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"treatment.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"mammogram\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(MLD)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"leukocyte\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+33857\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"taking\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"received\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Modulus\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(Celularity),\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"2024-2034\\\\\\\"\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"generating\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"available.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+298\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(AP)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"CD19-directed\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"antigenindependent\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"executi\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"ide-cel)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"European\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Co.s\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"GILD\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"expectations\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Incs\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Williams\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"launched\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"treatment-free\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"$-1.03\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"next-generation\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"refractory\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"N.J.,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"interview\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"fourfold\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"PRINCETON,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(idecabtagene\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Perettie,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"slow-growing\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"chimeric\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Aurora\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+3889\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"WIRE)--Legend\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Selection,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"engineering,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"advanc\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+2580\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"attack\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"T-based\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+5138\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Analysis\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"specific\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"N.J.--(BUSINESS\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+1867\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"worked,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"regions\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Foot\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Wiedermann\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+2464\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"focusing\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"interest\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Phase\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"glimmer\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"project\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Cindy\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Squibb's\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"immuno-oncology\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"EPS,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Fadda\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"nothing\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+5327\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Bioworks\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"ADCT\\u00a0isn't\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(NYSE:ADCT)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"testing\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(Le\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"testsWASHINGTON\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"collaborative\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"charge\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Indias\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"misses\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"PARK,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Celularity\\u00a0Inc.\\\\r\\\\n\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"reprogramming\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"FLORHAM\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(NYSE:BMY)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"immunotherapies\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+3681\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"NYSE:BMY)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"second\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"allogeneic\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+5939\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Born\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"country\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"indigenously-developed\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"expectations.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+3838\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"antigen\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"investigators\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Reported\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"respite\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"(CAR)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Ginkgo\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"recogni\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"2026.In\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"vicleucel;\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"helped\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"providing\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Commission\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"liso-cel),\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"effort\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"MUMBAI,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+1987\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"battling\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Forecast\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Droupadi\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"-The\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"market\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"CAR-TEAM\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"academ\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"maraleucel,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+49715\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"LEGN)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Reuters,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"SOMERSET,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"DNA)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"where\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"expe\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"CELU)\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"for\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"fast-growing\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"dis\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+21376\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+3963\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"patients.\\\\r\\\\nA\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"biotech's\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"treatment.\\\\r\\\\nIn\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Wednesday,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"overseas,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"countrys\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"2024\\\\r\\\\nADC\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Breyanzi,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"processes,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"last-ditch\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"least\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Corporation\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+3862\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"expanded\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"HOUSTON,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"increase\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"marking\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"tumor,\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"MRKR),\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Hiscox\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"$-0.47.\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"relapse\\\\r\\\\n\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+288\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"maraleucel;\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"hailing\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+5190\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Murmu\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+291\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Wasmuth\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"placental-derived\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"product\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"shrank\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+290\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"fitting\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"offering.\\\\r\\\\nThe\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"true\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"design\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"liso-\\u2026\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+3685\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Abecma\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"quadruple\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"acquisition\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"[+7930\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"Marker\\\",\\\"quantidade\\\":1}\", \"{\\\"palavra\\\":\\\"BOSTON\\\",\\\"quantidade\\\":1}\"]\n"
     ]
    },
    {
     "output_type": "display_data",
     "data": {
      "text/html": [
       "<style scoped>\n",
       "  .ansiout {\n",
       "    display: block;\n",
       "    unicode-bidi: embed;\n",
       "    white-space: pre-wrap;\n",
       "    word-wrap: break-word;\n",
       "    word-break: break-all;\n",
       "    font-family: \"Menlo\", \"Monaco\", \"Consolas\", \"Ubuntu Mono\", \"Source Code Pro\", monospace;\n",
       "    font-size: 13px;\n",
       "    color: #555;\n",
       "    margin-left: 4px;\n",
       "    line-height: 19px;\n",
       "  }\n",
       "</style>"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "arguments": {},
       "data": "",
       "errorSummary": "Cancelled",
       "errorTraceType": "html",
       "metadata": {},
       "type": "ipynbError"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "consumer = KafkaConsumer(\"rank_palavras\", bootstrap_servers=[\"localhost:9092\"],auto_offset_reset='earliest')\n",
    "\n",
    "for message in consumer:\n",
    "    print(message.value.decode('utf-8'))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "24cc6660-cdd2-4bf9-bff4-c120668377b2",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\"{\\\"dia\\\":21,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":24}\", \"{\\\"dia\\\":20,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":17}\", \"{\\\"dia\\\":15,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":17}\", \"{\\\"dia\\\":14,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":17}\", \"{\\\"dia\\\":2,\\\"mes\\\":4,\\\"ano\\\":2024,\\\"quantidade\\\":15}\", \"{\\\"dia\\\":4,\\\"mes\\\":4,\\\"ano\\\":2024,\\\"quantidade\\\":14}\", \"{\\\"dia\\\":28,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":12}\", \"{\\\"dia\\\":13,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":11}\", \"{\\\"dia\\\":27,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":10}\", \"{\\\"dia\\\":1,\\\"mes\\\":4,\\\"ano\\\":2024,\\\"quantidade\\\":9}\", \"{\\\"dia\\\":18,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":9}\", \"{\\\"dia\\\":25,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":8}\", \"{\\\"dia\\\":19,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":7}\", \"{\\\"dia\\\":22,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":7}\", \"{\\\"dia\\\":7,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":7}\", \"{\\\"dia\\\":29,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":7}\", \"{\\\"dia\\\":12,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":6}\", \"{\\\"dia\\\":30,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":6}\", \"{\\\"dia\\\":8,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":5}\", \"{\\\"dia\\\":16,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":5}\", \"{\\\"dia\\\":26,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":5}\", \"{\\\"dia\\\":23,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":4}\", \"{\\\"dia\\\":11,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":4}\", \"{\\\"dia\\\":3,\\\"mes\\\":4,\\\"ano\\\":2024,\\\"quantidade\\\":4}\", \"{\\\"dia\\\":31,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":3}\", \"{\\\"dia\\\":17,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":3}\", \"{\\\"dia\\\":24,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":3}\", \"{\\\"dia\\\":6,\\\"mes\\\":4,\\\"ano\\\":2024,\\\"quantidade\\\":3}\", \"{\\\"dia\\\":5,\\\"mes\\\":4,\\\"ano\\\":2024,\\\"quantidade\\\":2}\", \"{\\\"dia\\\":6,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":2}\", \"{\\\"dia\\\":10,\\\"mes\\\":3,\\\"ano\\\":2024,\\\"quantidade\\\":1}\"]\n"
     ]
    },
    {
     "output_type": "display_data",
     "data": {
      "text/html": [
       "<style scoped>\n",
       "  .ansiout {\n",
       "    display: block;\n",
       "    unicode-bidi: embed;\n",
       "    white-space: pre-wrap;\n",
       "    word-wrap: break-word;\n",
       "    word-break: break-all;\n",
       "    font-family: \"Menlo\", \"Monaco\", \"Consolas\", \"Ubuntu Mono\", \"Source Code Pro\", monospace;\n",
       "    font-size: 13px;\n",
       "    color: #555;\n",
       "    margin-left: 4px;\n",
       "    line-height: 19px;\n",
       "  }\n",
       "</style>"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "arguments": {},
       "data": "",
       "errorSummary": "Cancelled",
       "errorTraceType": "html",
       "metadata": {},
       "type": "ipynbError"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "consumer = KafkaConsumer(\"quantidades_data\", bootstrap_servers=[\"localhost:9092\"],auto_offset_reset='earliest')\n",
    "\n",
    "for message in consumer:\n",
    "    print(message.value.decode('utf-8'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "cellMetadata": {
      "byteLimit": 2048000,
      "rowLimit": 10000
     },
     "inputWidgets": {},
     "nuid": "362c1dcb-f75d-440a-9064-1854da139ad9",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "output_type": "stream",
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[\"{\\\"source_name\\\":\\\"ETF Daily News\\\",\\\"author\\\":\\\"MarketBeat News\\\",\\\"quantidade\\\":13}\", \"{\\\"source_name\\\":\\\"Investing.com\\\",\\\"author\\\":\\\"Investing.com\\\",\\\"quantidade\\\":9}\", \"{\\\"source_name\\\":\\\"InvestorsObserver\\\",\\\"author\\\":\\\"InvestorsObserver\\\",\\\"quantidade\\\":6}\", \"{\\\"source_name\\\":\\\"GlobeNewswire\\\",\\\"author\\\":\\\"Research and Markets\\\",\\\"quantidade\\\":5}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"William A. Haseltine, Contributor, \\\\n William A. Haseltine, Contributor\\\\n https://www.forbes.com/sites/williamhaseltine/\\\",\\\"quantidade\\\":5}\", \"{\\\"source_name\\\":\\\"Phys.Org\\\",\\\"author\\\":\\\"Science X\\\",\\\"quantidade\\\":5}\", \"{\\\"source_name\\\":\\\"Singularity Hub\\\",\\\"author\\\":\\\"Shelly Fan\\\",\\\"quantidade\\\":5}\", \"{\\\"source_name\\\":\\\"Biztoc.com\\\",\\\"author\\\":\\\"benzinga.com\\\",\\\"quantidade\\\":5}\", \"{\\\"source_name\\\":\\\"Www.abc.es\\\",\\\"author\\\":\\\"(abc)\\\",\\\"quantidade\\\":4}\", \"{\\\"source_name\\\":\\\"Bengreenfieldlife.com\\\",\\\"author\\\":\\\"support@bengreenfieldfitness.com (Ben Greenfield)\\\",\\\"quantidade\\\":4}\", \"{\\\"source_name\\\":\\\"WebMD\\\",\\\"author\\\":\\\"https://www.facebook.com/WebMD\\\",\\\"quantidade\\\":4}\", \"{\\\"source_name\\\":\\\"rt\\\",\\\"author\\\":\\\"RT en Espa\\u00f1ol\\\\n , RT en Espa\\u00f1ol\\\",\\\"quantidade\\\":3}\", \"{\\\"source_name\\\":\\\"ars-technica\\\",\\\"author\\\":\\\"Beth Mole\\\",\\\"quantidade\\\":3}\", \"{\\\"source_name\\\":\\\"Sputnikglobe.com\\\",\\\"author\\\":\\\"Chimauchem  Nwosu\\\",\\\"quantidade\\\":3}\", \"{\\\"source_name\\\":\\\"Investing.com\\\",\\\"author\\\":\\\"Reuters\\\",\\\"quantidade\\\":3}\", \"{\\\"source_name\\\":\\\"GlobeNewswire\\\",\\\"author\\\":\\\"Mustang Bio, Inc.\\\",\\\"quantidade\\\":3}\", \"{\\\"source_name\\\":\\\"Gizmodo.com\\\",\\\"author\\\":\\\"Ed Cara\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Securitylab.ru\\\",\\\"author\\\":\\\"Alexander Antipov\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Ferra.ru\\\",\\\"author\\\":\\\"\\u0411\\u0443\\u043b\\u0430\\u0442 \\u041a\\u0430\\u0440\\u043c\\u0430\\u043a\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"The Conversation Africa\\\",\\\"author\\\":\\\"Christopher Rudge, Law lecturer, University of Sydney\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Asriran.com\\\",\\\"author\\\":\\\"info@asriran.com\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Ilfattoquotidiano.it\\\",\\\"author\\\":\\\"F. Q.\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"ScienceAlert\\\",\\\"author\\\":\\\"Christopher Rudge, The Conversation\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Metropoles.com\\\",\\\"author\\\":\\\"Beth\\u00e2nia Nunes\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Phys.Org\\\",\\\"author\\\":\\\"Zhang Nannan\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Theness.com\\\",\\\"author\\\":\\\"Steven Novella\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Naturalnews.com\\\",\\\"author\\\":\\\"S.D. Wells\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Raw Story\\\",\\\"author\\\":\\\"Agence France-Presse\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"ScienceAlert\\\",\\\"author\\\":\\\"Mike McRae\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"The Boston Globe\\\",\\\"author\\\":\\\"Jonathan Saltzman\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"Katie Jennings, Forbes Staff, \\\\n Katie Jennings, Forbes Staff\\\\n https://www.forbes.com/sites/katiejennings/\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Nakedcapitalism.com\\\",\\\"author\\\":\\\"Yves Smith\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"GlobeNewswire\\\",\\\"author\\\":\\\"Marker Therapeutics\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Yahoo Entertainment\\\",\\\"author\\\":\\\"Insider Monkey Transcripts\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"abc-news\\\",\\\"author\\\":\\\"LAURAN NEERGAARD AP medical writer\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Harvard School of Engineering and Applied Sciences\\\",\\\"author\\\":\\\"gazetteterrymurphy\\\",\\\"quantidade\\\":2}\", \"{\\\"source_name\\\":\\\"Plos.org\\\",\\\"author\\\":\\\"Peng Chen, Jin Zhou, Huan Liu, Erchi Zhou, Boxiao He, Yankang Wu, Hongjian Wang, Zaiqiao Sun, Chonil Paek, Jun Lei, Yongshun Chen, Xinghua Zhang, Lei Yin\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Fast Company\\\",\\\"author\\\":\\\"Adam Bluestein\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Nplus1.ru\\\",\\\"author\\\":\\\"\\u0410\\u043b\\u044c\\u043f\\u0438\\u043d\\u0430 \\u043d\\u043e\\u043d-\\u0444\\u0438\\u043a\\u0448\\u043d\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"cnn\\\",\\\"author\\\":\\\"Gonzalo Zegarra\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"N-tv.de\\\",\\\"author\\\":\\\"n-tv NACHRICHTEN\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"the-times-of-india\\\",\\\"author\\\":\\\"etimes.in\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Donanimhaber.com\\\",\\\"author\\\":\\\"Metin Akp\\u0131nar\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Abril.com.br\\\",\\\"author\\\":\\\"Paula Felix\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Xataka.com.mx\\\",\\\"author\\\":\\\"Pablo Hern\\u00e1ndez\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Futura\\\",\\\"author\\\":\\\"St\\u00e9phanie Le Guillou, Journaliste Sant\\u00e9\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Publico.es\\\",\\\"author\\\":\\\"P\\u00fablico / Agencias\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Xataka.com.mx\\\",\\\"author\\\":\\\"C\\u00e9sar Aguilla\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"BBC News\\\",\\\"author\\\":\\\"https://www.facebook.com/bbcnews\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Odatv.com\\\",\\\"author\\\":\\\"Odatv\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Elperiodico.com\\\",\\\"author\\\":\\\"Idoya Noain\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"The Boston Globe\\\",\\\"author\\\":\\\"Catherine Carlock, Jonathan Saltzman\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"ars-technica\\\",\\\"author\\\":\\\"Elizabeth Rayne\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Plos.org\\\",\\\"author\\\":\\\"Suhan Ma, Xuyang Ni, Shimin Chen, Xiaomu Qiao, Xuejiao Xu, Weizhe Chen, Jackson Champer, Jia Huang\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Dissapore.com\\\",\\\"author\\\":\\\"Chiara Cajelli\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Habr.com\\\",\\\"author\\\":\\\"IBS_habrablog (IBS)\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Adevarul.ro\\\",\\\"author\\\":\\\"Florina Ilicea\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"il-sole-24-ore\\\",\\\"author\\\":\\\"di Rosanna Magnano\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Www.nkj.ru\\\",\\\"author\\\":\\\"\\u0420\\u0435\\u0434\\u0430\\u043a\\u0446\\u0438\\u044f \\u0436\\u0443\\u0440\\u043d\\u0430\\u043b\\u0430 \\u041d\\u0430\\u0443\\u043a\\u0430 \\u0438 \\u0436\\u0438\\u0437\\u043d\\u044c\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Eldiario.es\\\",\\\"author\\\":\\\"EFE/elDiario.es\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"GrrlScientist, Senior Contributor, \\\\n GrrlScientist, Senior Contributor\\\\n https://www.forbes.com/sites/grrlscientist/\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Study Finds\\\",\\\"author\\\":\\\"StudyFinds Staff\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Huffingtonpost.es\\\",\\\"author\\\":\\\"Elena Santos\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Novate.ru\\\",\\\"author\\\":\\\"//www.facebook.com/novate\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Plos.org\\\",\\\"author\\\":\\\"Jialiang Sun, Jun Guo, Jian Liu\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Tass.ru\\\",\\\"author\\\":\\\"\\u0422\\u0410\\u0421\\u0421\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Plos.org\\\",\\\"author\\\":\\\"Christopher J. Johnson, Florian Razy-Krajka, Fan Zeng, Katarzyna M. Piekarz, Shweta Biliya, Ute Rothb\\u00e4cher, Alberto Stolfi\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Isna.ir\\\",\\\"author\\\":\\\"\\u062e\\u0628\\u0631\\u06af\\u0632\\u0627\\u0631\\u06cc \\u0627\\u06cc\\u0633\\u0646\\u0627 | \\u0635\\u0641\\u062d\\u0647 \\u0627\\u0635\\u0644\\u06cc |  ISNA News Agency\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Yahoo Entertainment\\\",\\\"author\\\":\\\"GuruFocus.com\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Sopitas.com\\\",\\\"author\\\":\\\"Gabriela Espinosa\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Eldiario.es\\\",\\\"author\\\":\\\"elDiario.es\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Hi-news.ru\\\",\\\"author\\\":\\\"\\u0410\\u043d\\u0434\\u0440\\u0435\\u0439 \\u0416\\u0443\\u043a\\u043e\\u0432\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Ferra.ru\\\",\\\"author\\\":\\\"\\u041d\\u0438\\u043a\\u043e\\u043b\\u0430\\u0439 \\u0428\\u0435\\u043b\\u043e\\u0444\\u0430\\u0441\\u0442\\u043e\\u0432\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Nationalgeographic.com.es\\\",\\\"author\\\":\\\"www.nationalgeographic.com.es, www.nationalgeographic.com.es\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Jotdown.es\\\",\\\"author\\\":\\\"Mart\\u00edn Sacrist\\u00e1n\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Isna.ir\\\",\\\"author\\\":\\\"\\u0647\\u0633\\u062a\\u06cc \\u0648\\u0641\\u0627\\u06cc\\u06cc\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"heise online\\\",\\\"author\\\":\\\"Marie-Claire Koch\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"heise online\\\",\\\"author\\\":\\\"Thomas Hoffmann\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Terra.com.br\\\",\\\"author\\\":\\\"DINO\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Lbl.gov\\\",\\\"author\\\":\\\"akovner\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Quartz India\\\",\\\"author\\\":\\\"Ed Cara / Gizmodo\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Microsiervos.com\\\",\\\"author\\\":\\\"wicho@microsiervos.com (Wicho)\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Scientific American\\\",\\\"author\\\":\\\"Carol Cardona, Michelle Kromm\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"el-mundo\\\",\\\"author\\\":\\\"Efe\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Uol.com.br\\\",\\\"author\\\":\\\"Renata Turbiani\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Uol.com.br\\\",\\\"author\\\":\\\"B\\u00e1rbara Giovani\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Technews.tw\\\",\\\"author\\\":\\\"Evan\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Eldiario.es\\\",\\\"author\\\":\\\"Daniel S\\u00e1nchez Caballero\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Internazionale.it\\\",\\\"author\\\":\\\"Internazionale\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"tagesschau.de\\\",\\\"author\\\":\\\"Leander Beil, BR\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Le HuffPost\\\",\\\"author\\\":\\\"Jules Castagni\\u00e9, Benjamin Houry\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Olhardigital.com.br\\\",\\\"author\\\":\\\"Leandro Costa Criscuolo\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Cracked.com\\\",\\\"author\\\":\\\"Ryan Menezes\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Olhardigital.com.br\\\",\\\"author\\\":\\\"Alessandro Di Lorenzo\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Uol.com.br\\\",\\\"author\\\":\\\"Gabriel Andrade\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Jandan.net\\\",\\\"author\\\":\\\"BALI\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Uol.com.br\\\",\\\"author\\\":\\\"Ag\\u00eancia Fapesp\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Elespanol.com\\\",\\\"author\\\":\\\"Marcos Dom\\u00ednguez\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"The Daily Caller\\\",\\\"author\\\":\\\"Mariane Angela\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Yahoo Entertainment\\\",\\\"author\\\":\\\"AFP\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Psychology Today\\\",\\\"author\\\":\\\"Robert T Muller Ph.D.\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"Eva Epker, Contributor, \\\\n Eva Epker, Contributor\\\\n https://www.forbes.com/sites/evaepker/\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"Susan Galer, SAP, \\\\n Susan Galer, SAP\\\\n https://www.forbes.com/sites/sap/people/susangaler/\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Psychology Today\\\",\\\"author\\\":\\\"Amelia Kelley Ph.D.\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"IndieWire\\\",\\\"author\\\":\\\"Erin Strecker\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Yahoo Entertainment\\\",\\\"author\\\":\\\"TipRanks\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Plos.org\\\",\\\"author\\\":\\\"Zhihui Liu, Xiyuan Zhang, Man Xu, Jason J. Hong, Amanda Ciardiello, Haiyan Lei, Jack F. Shern, Carol J. Thiele\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"The New York Review of Books\\\",\\\"author\\\":\\\"Jerome Groopman\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Yahoo Entertainment\\\",\\\"author\\\":\\\"GuruFocus Research\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Advocate.com\\\",\\\"author\\\":\\\"Ryan Adamczeski\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"nbc-news\\\",\\\"author\\\":\\\"Arthur Allen | KFF Health News\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"International Business Times\\\",\\\"author\\\":\\\"Issam AHMED\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Lemire.me\\\",\\\"author\\\":\\\"Daniel Lemire\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Phys.Org\\\",\\\"author\\\":\\\"Anne Trafton\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Raw Story\\\",\\\"author\\\":\\\"DPA International\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"Maggie McGrath, Forbes Staff, \\\\n Maggie McGrath, Forbes Staff\\\\n https://www.forbes.com/sites/maggiemcgrath/\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"Joshua Cohen, Senior Contributor, \\\\n Joshua Cohen, Senior Contributor\\\\n https://www.forbes.com/sites/joshuacohen/\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Boston Herald\\\",\\\"author\\\":\\\"Tribune News Service\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Elifesciences.org\\\",\\\"author\\\":\\\"pierce.ogden@gmail.com (George M Church), pierce.ogden@gmail.com (Nina K Jain), pierce.ogden@gmail.com (Pierce J Ogden)\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"time\\\",\\\"author\\\":\\\"Gerry Smith/Bloomberg\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Queerty.com\\\",\\\"author\\\":\\\"David Hudson\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"GlobeNewswire\\\",\\\"author\\\":\\\"The Lundquist Institute for Biomedical Innovation\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"Alex Knapp, Forbes Staff, \\\\n Alex Knapp, Forbes Staff\\\\n https://www.forbes.com/sites/alexknapp/\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Live Science\\\",\\\"author\\\":\\\"emily.cooke@futurenet.com (Emily Cooke)\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Lescienze.it\\\",\\\"author\\\":\\\"redazione@lescienze.it (Redazione Le Scienze Italia)\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Royal Society of Chemistry\\\",\\\"author\\\":\\\"Puja Sandbhor, Pranoti Palkar, Sakshi Bhat, Geofrey John, Jayant S. Goda\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Plos.org\\\",\\\"author\\\":\\\"Shang Rumin, Xiangming Han, Cui Zeng, Fei Lv, Rong Fang, Rongrong Gong, Xiaochang Tian, Xiangwu Ding\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"Victoria Forster, Contributor, \\\\n Victoria Forster, Contributor\\\\n https://www.forbes.com/sites/victoriaforster/\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"WebMD\\\",\\\"author\\\":\\\"Evan Starkman\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"GuruFocus, Contributor, \\\\n GuruFocus, Contributor\\\\n https://www.forbes.com/sites/gurufocus/\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Shtfplan.com\\\",\\\"author\\\":\\\"Mac Slavo\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"GlobeNewswire\\\",\\\"author\\\":\\\"PolTREG S.A.\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"the-times-of-india\\\",\\\"author\\\":\\\"Anirban Chowdhury\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"nbc-news\\\",\\\"author\\\":\\\"Kaitlin Sullivan\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"GlobeNewswire\\\",\\\"author\\\":\\\"Immix Biopharma, Inc.\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Globalresearch.ca\\\",\\\"author\\\":\\\"Dr. Joseph Mercola\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"GlobeNewswire\\\",\\\"author\\\":\\\"TBRC Business Research PVT LTD\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"the-irish-times\\\",\\\"author\\\":\\\"Arlene Harris\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"GlobeNewswire\\\",\\\"author\\\":\\\"Caribou Biosciences, Inc.\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"ComingSoon.net\\\",\\\"author\\\":\\\"Apoorv Rastogi\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Phys.Org\\\",\\\"author\\\":\\\"Mario Aguilera\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"MIT Technology Review\\\",\\\"author\\\":\\\"Rhiannon Williams\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Quartz India\\\",\\\"author\\\":\\\"Bruce Gil\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Study Finds\\\",\\\"author\\\":\\\"StudyFinds\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Biztoc.com\\\",\\\"author\\\":\\\"fiercepharma.com\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"WebMD\\\",\\\"author\\\":\\\"Kathleen Doheny\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"New Atlas\\\",\\\"author\\\":\\\"Michael Irving\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"The Atlantic\\\",\\\"author\\\":\\\"Sarah Zhang\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"bbc-news\\\",\\\"author\\\":\\\"https://www.facebook.com/bbcnews\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"Mehb Khoja, Forbes Councils Member, \\\\n Mehb Khoja, Forbes Councils Member\\\\n https://www.forbes.com/sites/forbesfinancecouncil/people/mehbkhoja/\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Adafruit.com\\\",\\\"author\\\":\\\"Zay\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"FDA.gov\\\",\\\"author\\\":\\\"FDA\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Biztoc.com\\\",\\\"author\\\":\\\"investors.com\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Forbes\\\",\\\"author\\\":\\\"Yola Robert, Senior Contributor, \\\\n Yola Robert, Senior Contributor\\\\n https://www.forbes.com/sites/yolarobert1/\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"BusinessLine\\\",\\\"author\\\":\\\"PT Jyothi Datta\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Plos.org\\\",\\\"author\\\":\\\"Martyn J. Hiscox, Alexandra Wasmuth, Chris L. Williams, Jaelle N. Foot, Guy E. Wiedermann, Valeria Fadda, Sara Boiani, Terri V. Cornforth, Karolina A. Wikiert, Shaun Bruton, Neil Cartwright, Victoria Elizabeth Anderson, Christopher S. Barnes, Joao V. Vieira, Ian Birch-Machin, Andrew B. Gerry, Karen Miller, Nicholas J. Pumphrey\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Biztoc.com\\\",\\\"author\\\":\\\"aol.com\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"associated-press\\\",\\\"author\\\":\\\"ap news\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Boston Herald\\\",\\\"author\\\":\\\"Meg Wingerter\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Thehillstimes.in\\\",\\\"author\\\":\\\"The Hills Times\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Phys.Org\\\",\\\"author\\\":\\\"Ian Scheffler\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"GlobeNewswire\\\",\\\"author\\\":\\\"Celularity Inc.\\\",\\\"quantidade\\\":1}\", \"{\\\"source_name\\\":\\\"Boston Herald\\\",\\\"author\\\":\\\"Rick Sobey\\\",\\\"quantidade\\\":1}\"]\n"
     ]
    },
    {
     "output_type": "display_data",
     "data": {
      "text/html": [
       "<style scoped>\n",
       "  .ansiout {\n",
       "    display: block;\n",
       "    unicode-bidi: embed;\n",
       "    white-space: pre-wrap;\n",
       "    word-wrap: break-word;\n",
       "    word-break: break-all;\n",
       "    font-family: \"Menlo\", \"Monaco\", \"Consolas\", \"Ubuntu Mono\", \"Source Code Pro\", monospace;\n",
       "    font-size: 13px;\n",
       "    color: #555;\n",
       "    margin-left: 4px;\n",
       "    line-height: 19px;\n",
       "  }\n",
       "</style>"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "arguments": {},
       "data": "",
       "errorSummary": "Cancelled",
       "errorTraceType": "html",
       "metadata": {},
       "type": "ipynbError"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "consumer = KafkaConsumer(\"quantidades_fonte_autor\", bootstrap_servers=[\"localhost:9092\"],auto_offset_reset='earliest')\n",
    "\n",
    "for message in consumer:\n",
    "    print(message.value.decode('utf-8'))"
   ]
  }
 ],
 "metadata": {
  "application/vnd.databricks.v1+notebook": {
   "dashboards": [],
   "language": "python",
   "notebookMetadata": {
    "pythonIndentUnit": 4
   },
   "notebookName": "PROJETO -  VERDADEIRO",
   "widgets": {}
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
